cached image

Douglas R. Galasko, MD - Publications

Affiliations: 
Neuroscience University of California, San Diego, La Jolla, CA 
Area:
Dementia
Website:
http://neurograd.ucsd.edu/faculty/detail.php?id=30

342 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Bernier RA, Banks SJ, Panizzon MS, Andrews MJ, Jacobs EG, Galasko DR, Shepherd AL, Akassoglou K, Sundermann EE. The neuroinflammatory marker sTNFR2 relates to worse cognition and tau in women across the Alzheimer's disease spectrum. Alzheimer's & Dementia (Amsterdam, Netherlands). 14: e12284. PMID 35386474 DOI: 10.1002/dad2.12284  0.386
2022 Scott GD, Arnold MR, Beach TG, Gibbons CH, Kanthasamy AG, Lebovitz RM, Lemstra AW, Shaw LM, Teunissen CE, Zetterberg H, Taylor AS, Graham TC, Boeve BF, Gomperts SN, Graff-Radford NR, ... ... Galasko DR, et al. Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology. 12: 805135. PMID 35173668 DOI: 10.3389/fneur.2021.805135  0.319
2022 Caldwell AB, Liu Q, Zhang C, Schroth GP, Galasko DR, Rynearson KD, Tanzi RE, Yuan SH, Wagner SL, Subramaniam S. Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 35084109 DOI: 10.1002/alz.12553  0.324
2021 Mengel D, Mok TH, Nihat A, Liu W, Rissman RA, Galasko D, Zetterberg H, Mead S, Collinge J, Walsh DM. NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression. Cells. 10. PMID 34944022 DOI: 10.3390/cells10123514  0.338
2021 Smirnov DS, Salmon DP, Galasko D, Goodwill VS, Hansen LA, Zhao Y, Edland SD, Léger GC, Peavy GM, Jacobs DM, Rissman R, Pizzo DP, Hiniker A. Association of Neurofibrillary Tangle Distribution With Age at Onset-Related Clinical Heterogeneity in Alzheimer Disease: An Autopsy Study. Neurology. PMID 34810247 DOI: 10.1212/WNL.0000000000013107  0.401
2021 Thomas KR, Bangen KJ, Edmonds EC, Weigand AJ, Walker KS, Bondi MW, Galasko DR. Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease-related declines. Alzheimer's & Dementia (Amsterdam, Netherlands). 13: e12238. PMID 34692978 DOI: 10.1002/dad2.12238  0.369
2021 Edmonds EC, Smirnov DS, Thomas KR, Graves LV, Bangen KJ, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Data-Driven vs Consensus Diagnosis of MCI: Enhanced Sensitivity for Detection of Clinical, Biomarker, and Neuropathologic Outcomes. Neurology. PMID 34376506 DOI: 10.1212/WNL.0000000000012600  0.309
2021 Bangen KJ, Smirnov DS, Delano-Wood L, Wierenga CE, Bondi MW, Salmon DP, Galasko D. Arterial stiffening acts synergistically with APOE genotype and AD biomarker status to influence memory in older adults without dementia. Alzheimer's Research & Therapy. 13: 121. PMID 34210365 DOI: 10.1186/s13195-021-00851-2  0.329
2021 Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, ... ... Galasko DR, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature Medicine. PMID 34155411 DOI: 10.1038/s41591-021-01369-8  0.338
2021 Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. The Lancet. Neurology. PMID 33933186 DOI: 10.1016/S1474-4422(21)00066-1  0.388
2021 Bangen KJ, Thomas KR, Weigand AJ, Edmonds EC, Clark AL, Solders S, Delano-Wood L, Galasko DR, Bondi MW. Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 33860596 DOI: 10.1002/alz.12324  0.316
2021 Smirnov DS, Galasko D, Hiniker A, Edland S, Salmon DP. Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease. Neurology. PMID 33722993 DOI: 10.1212/WNL.0000000000011772  0.419
2021 Ryman SG, Yutsis M, Tian L, Henderson VW, Montine TJ, Salmon DP, Galasko D, Poston KL. Cognition at Each Stage of Lewy Body Disease with Co-occurring Alzheimer's Disease Pathology. Journal of Alzheimer's Disease : Jad. PMID 33646154 DOI: 10.3233/JAD-201187  0.382
2020 Sandau US, Wiedrick JT, Smith SJ, McFarland TJ, Lusardi TA, Lind B, Harrington CA, Lapidus JA, Galasko DR, Quinn JF, Saugstad JA. Performance of Validated MicroRNA Biomarkers for Alzheimer's Disease in Mild Cognitive Impairment. Journal of Alzheimer's Disease : Jad. PMID 32955460 DOI: 10.3233/JAD-200396  0.496
2020 Weigand AJ, Bondi MW, Thomas KR, Campbell NL, Galasko DR, Salmon DP, Sewell D, Brewer JB, Feldman HH, Delano-Wood L. Association of anticholinergic medication and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology. PMID 32878992 DOI: 10.1212/Wnl.0000000000010643  0.441
2020 Mollenhauer B, Dakna M, Kruse N, Galasko D, Foroud T, Zetterberg H, Schade S, Gera RG, Wang W, Gao F, Frasier M, Chahine LM, Coffey CS, Singleton AB, Simuni T, et al. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 32798333 DOI: 10.1002/Mds.28206  0.316
2020 Peavy GM, Jenkins CW, Little EA, Gigliotti C, Calcetas A, Edland SD, Brewer JB, Galasko D, Salmon DP. Community memory screening as a strategy for recruiting older adults into Alzheimer's disease research. Alzheimer's Research & Therapy. 12: 78. PMID 32605603 DOI: 10.1186/s13195-020-00643-0  0.41
2020 Gollan TH, Smirnov DS, Salmon DP, Galasko D. Failure to stop autocorrect errors in reading aloud increases in aging especially with a positive biomarker for Alzheimer's disease. Psychology and Aging. PMID 32584071 DOI: 10.1037/Pag0000550  0.399
2020 Schindler SE, Jicha GA, Nelson PT, Keene CD, Blennow K, Molinuevo JL, Masters CL, Hansson O, Teunissen CE, Galasko D, Shaw LM, Levey AI. Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. Journal of Alzheimer's Disease : Jad. PMID 32568212 DOI: 10.3233/JAD-200684  0.402
2020 Sundermann EE, Panizzon MS, Chen X, Andrews M, Galasko D, Banks SJ. Sex differences in Alzheimer's-related Tau biomarkers and a mediating effect of testosterone. Biology of Sex Differences. 11: 33. PMID 32560743 DOI: 10.1186/s13293-020-00310-x  0.426
2020 Irwin DJ, Felder J, Coffey CS, Caspell-Garcia C, Kang JH, Simuni T, Foroud T, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Weintraub D, Mollenhauer B, ... Galasko DR, et al. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. Annals of Neurology. PMID 32542885 DOI: 10.1002/Ana.25811  0.431
2020 Smirnov DS, Galasko D, Edland SD, Filoteo JV, Hansen LA, Salmon DP. Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. Neurology. PMID 32332125 DOI: 10.1212/Wnl.0000000000009434  0.496
2020 McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, Kantarci K, Muscio C, O'Brien JT, Postuma RB, Aarsland D, Ballard C, Bonanni L, Donaghy P, Emre M, ... ... Galasko D, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. PMID 32241955 DOI: 10.1212/Wnl.0000000000009323  0.442
2020 Orme T, Hernandez D, Ross OA, Kun-Rodrigues C, Darwent L, Shepherd CE, Parkkinen L, Ansorge O, Clark L, Honig LS, Marder K, Lemstra A, Rogaeva E, St George-Hyslop P, Londos E, ... ... Galasko D, et al. Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications. 8: 5. PMID 31996268 DOI: 10.1186/S40478-020-0879-Z  0.436
2020 Gate D, Saligrama N, Leventhal O, Yang AC, Unger MS, Middeldorp J, Chen K, Lehallier B, Channappa D, De Los Santos MB, McBride A, Pluvinage J, Elahi F, Tam GK, Kim Y, ... ... Galasko DR, et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease. Nature. PMID 31915375 DOI: 10.1038/S41586-019-1895-7  0.38
2019 Galasko D, Xiao M, Xu D, Smirnov D, Salmon DP, Dewit N, Vanbrabant J, Jacobs D, Vanderstichele H, Vanmechelen E, Worley P. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 5: 871-882. PMID 31853477 DOI: 10.1016/j.trci.2019.11.002  0.491
2019 Cha DJ, Mengel D, Mustapic M, Liu W, Selkoe DJ, Kapogiannis D, Galasko D, Rissman RA, Bennett DA, Walsh DM. miR-212 and miR-132 Are Downregulated in Neurally Derived Plasma Exosomes of Alzheimer's Patients. Frontiers in Neuroscience. 13: 1208. PMID 31849573 DOI: 10.3389/Fnins.2019.01208  0.398
2019 Reas ET, Hagler DJ, Kuperman JM, Wierenga CE, Galasko D, White NS, Dale AM, Banks SJ, McEvoy LK, Brewer JB. Associations Between Microstructure, Amyloid, and Cognition in Amnestic Mild Cognitive Impairment and Dementia. Journal of Alzheimer's Disease : Jad. PMID 31796676 DOI: 10.3233/Jad-190871  0.463
2019 Saijo E, Metrick MA, Koga S, Parchi P, Litvan I, Spina S, Boxer A, Rojas JC, Galasko D, Kraus A, Rossi M, Newell K, Zanusso G, Grinberg LT, Seeley WW, et al. Correction to: 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathologica. PMID 31748840 DOI: 10.1007/S00401-019-02092-Y  0.304
2019 Hays CC, Zlatar ZZ, Meloy MJ, Osuna J, Liu TT, Galasko DR, Wierenga CE. Anterior Cingulate Structure and Perfusion Is Associated with Cerebrospinal Fluid Tau Among Cognitively Normal Older Adult APOEɛ4 Carriers. Journal of Alzheimer's Disease : Jad. PMID 31743999 DOI: 10.3233/Jad-190504  0.418
2019 Saijo E, Metrick MA, Koga S, Parchi P, Litvan I, Spina S, Boxer A, Rojas JC, Galasko D, Kraus A, Rossi M, Newell K, Zanusso G, Grinberg LT, Seeley WW, et al. 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathologica. PMID 31616982 DOI: 10.1007/S00401-019-02080-2  0.338
2019 Thomas KR, Edmonds EC, Eppig JS, Wong CG, Weigand AJ, Bangen KJ, Jak AJ, Delano-Wood L, Galasko DR, Salmon DP, Edland SD, Bondi MW. MCI-to-normal reversion using neuropsychological criteria in the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31495605 DOI: 10.1016/J.Jalz.2019.06.4948  0.467
2019 Chahine LM, Siderowf A, Barnes J, Seedorff N, Caspell-Garcia C, Simuni T, Coffey CS, Galasko D, Mollenhauer B, Arnedo V, Daegele N, Frasier M, Tanner C, Kieburtz K, Marek K, et al. Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures. Journal of Parkinson's Disease. PMID 31450510 DOI: 10.3233/Jpd-181518  0.324
2019 Smirnov DS, Stasenko A, Salmon DP, Galasko D, Brewer JB, Gollan TH. Distinct structural correlates of the dominant and nondominant languages in bilinguals with Alzheimer's disease (AD). Neuropsychologia. 132: 107131. PMID 31271821 DOI: 10.1016/J.Neuropsychologia.2019.107131  0.399
2019 Guerreiro R, Escott-Price V, Hernandez DG, Kun-Rodrigues C, Ross OA, Orme T, Neto JL, Carmona S, Dehghani N, Eicher JD, Shepherd C, Parkkinen L, Darwent L, Heckman MG, Scholz SW, ... ... Galasko D, et al. Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease. PMID 30953760 DOI: 10.1016/J.Nbd.2019.04.004  0.392
2019 Peterson B, Armstrong M, Galasko D, Galvin JE, Goldman J, Irwin D, Paulson H, Kaufer D, Leverenz J, Lunde A, McKeith IG, Siderowf A, Taylor A, Amodeo K, Barrett M, et al. Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. Alzheimer's Research & Therapy. 11: 23. PMID 30867052 DOI: 10.1186/S13195-019-0476-1  0.393
2019 Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G, Li Y, Hassenstab J, Aschenbrenner A, Hornbeck R, Jack CR, ... ... Galasko D, et al. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. Brain : a Journal of Neurology. PMID 30753379 DOI: 10.1093/Brain/Awz019  0.464
2019 Edmonds EC, McDonald CR, Marshall A, Thomas KR, Eppig J, Weigand AJ, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Early versus late MCI: Improved MCI staging using a neuropsychological approach. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30737119 DOI: 10.1016/J.Jalz.2018.12.009  0.436
2019 Wiedrick JT, Phillips JI, Lusardi TA, McFarland TJ, Lind B, Sandau US, Harrington CA, Lapidus JA, Galasko DR, Quinn JF, Saugstad JA. Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid. Journal of Alzheimer's Disease : Jad. PMID 30689565 DOI: 10.3233/JAD-180539  0.355
2019 Weissberger GH, Gollan TH, Bondi MW, Nation DA, Hansen LA, Galasko D, Salmon DP. Neuropsychological Deficit Profiles, Vascular Risk Factors, and Neuropathological Findings in Hispanic Older Adults with Autopsy-Confirmed Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 67: 291-302. PMID 30636736 DOI: 10.3233/Jad-180351  0.519
2019 Korthauer LE, Salmon DP, Festa EK, Galasko D, Heindel WC. Alzheimer's disease and the processing of uncertainty during choice task performance: Executive dysfunction within the Hick-Hyman law. Journal of Clinical and Experimental Neuropsychology. 1-10. PMID 30632903 DOI: 10.1080/13803395.2018.1564813  0.437
2019 Thomas KR, Eppig JS, Weigand AJ, Edmonds EC, Wong CG, Jak AJ, Delano-Wood L, Galasko DR, Salmon DP, Edland SD, Bondi MW. Artificially low mild cognitive impairment to normal reversion rate in Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30610833 DOI: 10.1016/J.Jalz.2018.10.008  0.449
2019 Galasko DR, Smirnov D, Salmon DP, De Wit N, Jacobs D, Vanbrabant J, Vanmechelen E, Vanderstichele HM, Xu D, Xiao M, Worley PF. CSF BIOMARKERS OF SYNAPTIC DAMAGE (NEUROGRANIN, SNAP25) AND INTERNEURON-DEPENDENT SYNAPTIC HOMEOSTASIS (NPTX2) IMPROVE DIAGNOSTIC CLASSIFICATION OF MCI AND AD AND CORRELATE WITH COGNITION Alzheimer's & Dementia. 15: P1626. DOI: 10.1016/j.jalz.2019.06.4859  0.384
2019 Levey AI, Lah JJ, Hu WT, Wingo TS, Hales CM, Manzanares C, Tansey MG, Goldstein DS, Zhao L, Galasko DR, Edland SD, Hanfelt J, Weinshenker D. O4-11-05: A PROOF OF CONCEPT PHASE II STUDY REPURPOSING ATOMOXETINE FOR NEUROPROTECTION IN MILD COGNITIVE IMPAIRMENT: EVIDENCE FOR TARGET ENGAGEMENT, REGULATION OF CSF BIOMARKERS, AND DISEASE-MODIFYING POTENTIAL Alzheimer's & Dementia. 15: P1263-P1264. DOI: 10.1016/J.Jalz.2019.06.4804  0.362
2019 Smirnov D, Salmon DP, Edland SD, Vanmechelen E, Vanderstichele HM, De Wit N, Vanbrabant J, Jacobs D, Xu D, Xiao M, Worley PF, Galasko DR. CSF BIOMARKERS OF AMYLOID, TAU AND SYNAPTIC DAMAGE (NEUROGRANIN, SNAP25) AND INTERNEURON-DEPENDENT SYNAPTIC HOMEOSTASIS (NPTX2) IN CSF AS PREDICTORS OF COGNITIVE PROGRESSION IN MCI AND AD Alzheimer's & Dementia. 15: P212-P213. DOI: 10.1016/j.jalz.2019.06.4556  0.415
2019 Galasko DR, Smirnov D, Edland SD, Worley PF, Vanmechelen E, Vanderstichele HM, Salmon DP. CSF BIOMARKERS RELATED TO NEURODEGENERATION AS PREDICTORS OF COGNITIVE PROGRESSION IN MCI AND ELDERLY CONTROLS Alzheimer's & Dementia. 15: P178-P179. DOI: 10.1016/j.jalz.2019.06.4377  0.4
2019 Smirnov D, Galasko DR, Filoteo JV, Edland SD, Hansen LA, Salmon DP. P4-362: DOMAIN-SPECIFIC COGNITIVE IMPAIRMENT AND LONGITUDINAL COGNITIVE DECLINE DIFFER IN PARKINSON'S DISEASE DEMENTIA (PDD), DEMENTIA WITH LEWY BODIES (DLB), AND ALZHEIMER'S DISEASE (AD) Alzheimer's & Dementia. 15: P1438-P1438. DOI: 10.1016/J.Jalz.2019.06.4033  0.515
2019 Marshall GA, Sikkes SAM, Amariglio R, Gatchel JR, Rentz D, Johnson KA, Langford O, Sun C, Donohue MC, Raman R, Aisen PS, Sperling RA, Galasko DR, Team AS. P4-245: The Association Between Instrumental Activities Of Daily Living And Cortical Amyloid In Cognitively Normal Older Adults Screening For The A4 Study Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.3908  0.327
2019 Eglit GM, Eppig JS, Thomas KR, Wong CG, Weigand AJ, Edmonds EC, Salmon DP, Galasko DR, Bondi MW. P4-206: COGNITIVE STAGE AND BIOMARKER PROFILE PREDICTORS OF DEMENTIA: A DISCRETE-TIME SURVIVAL ANALYSIS Alzheimer's & Dementia. 15: P1355-P1355. DOI: 10.1016/J.Jalz.2019.06.3869  0.371
2019 Jacobs DM, Festa EK, Salmon DP, Galasko DR, Heindel WC. P2-470: VISUAL SENSORY BINDING IN PRECLINICAL AD Alzheimer's & Dementia. 15: P797-P797. DOI: 10.1016/j.jalz.2019.06.2877  0.331
2019 Edmonds EC, Thomas KR, Eppig JS, Delano-Wood L, McDonald CR, Galasko DR, Salmon DP, Bondi MW. P2-444: DIFFERING LONGITUDINAL NEUROPSYCHOLOGICAL PROFILES AND TRAJECTORIES OF EMPIRICALLY DERIVED SUBTYPES OF MCI Alzheimer's & Dementia. 15: P784-P784. DOI: 10.1016/J.Jalz.2019.06.2851  0.311
2019 Reas ET, Hagler DJ, White N, Kuperman J, Bartsch H, Wierenga C, Galasko DR, Dale AM, Banks SJ, Mcevoy L, Brewer JB. P1-414: ASSOCIATION OF BRAIN MICROSTRUCTURE AND AMYLOID-β WITH COGNITIVE DECLINE IN EARLY ALZHEIMER'S DISEASE Alzheimer's & Dementia. 15: P421-P421. DOI: 10.1016/J.Jalz.2019.06.1019  0.434
2018 Smirnov DS, Galasko D, Hansen LA, Edland SD, Brewer JB, Salmon DP. Trajectories of cognitive decline differ in hippocampal sclerosis and Alzheimer's disease. Neurobiology of Aging. 75: 169-177. PMID 30579145 DOI: 10.1016/J.Neurobiolaging.2018.11.015  0.537
2018 Kun-Rodrigues C, Orme T, Carmona S, Hernandez DG, Ross OA, Eicher JD, Shepherd C, Parkkinen L, Darwent L, Heckman MG, Scholz SW, Troncoso JC, Pletnikova O, Dawson T, Rosenthal L, ... ... Galasko D, et al. A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging. PMID 30448004 DOI: 10.1016/J.Neurobiolaging.2018.10.019  0.364
2018 Chen Z, Mengel D, Keshavan A, Rissman RA, Billinton A, Perkinton M, Percival-Alwyn J, Schultz A, Properzi M, Johnson K, Selkoe DJ, Sperling RA, Patel P, Zetterberg H, Galasko D, et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30419228 DOI: 10.1016/J.Jalz.2018.09.010  0.444
2018 Soria JA, Huisa BN, Edland SD, Litvan I, Peavy GM, Salmon DP, Hansen LA, Galasko DR, Brewer JB, González HM, Rissman RA. Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers. Journal of Alzheimer's Disease : Jad. PMID 30412501 DOI: 10.3233/Jad-180789  0.497
2018 Besser L, Kukull W, Knopman DS, Chui H, Galasko D, Weintraub S, Jicha G, Carlsson C, Burns J, Quinn J, Sweet RA, Rascovsky K, Teylan M, Beekly D, Thomas G, et al. Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Disease and Associated Disorders. PMID 30376508 DOI: 10.1097/Wad.0000000000000279  0.355
2018 Shaw LM, Arias J, Blennow K, Galasko D, Molinuevo JL, Salloway S, Schindler S, Carrillo MC, Hendrix JA, Ross A, Illes J, Ramus C, Fifer S. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30316776 DOI: 10.1016/j.jalz.2018.07.220  0.302
2018 Reas ET, Hagler DJ, White NS, Kuperman JM, Bartsch H, Wierenga CE, Galasko D, Brewer JB, Dale AM, McEvoy LK. Microstructural brain changes track cognitive decline in mild cognitive impairment. Neuroimage. Clinical. 20: 883-891. PMID 30290303 DOI: 10.1016/J.Nicl.2018.09.027  0.421
2018 Edmonds EC, Weigand AJ, Thomas KR, Eppig J, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Increasing Inaccuracy of Self-Reported Subjective Cognitive Complaints Over 24 Months in Empirically Derived Subtypes of Mild Cognitive Impairment. Journal of the International Neuropsychological Society : Jins. 24: 842-853. PMID 30278855 DOI: 10.1017/S1355617718000486  0.402
2018 Ramos EM, Carecchio M, Lemos R, Ferreira J, Legati A, Sears RL, Hsu SC, Panteghini C, Magistrelli L, Salsano E, Esposito S, Taroni F, Richard AC, Tranchant C, Anheim M, ... ... Galasko D, et al. Primary brain calcification: an international study reporting novel variants and associated phenotypes. European Journal of Human Genetics : Ejhg. PMID 29955172 DOI: 10.1038/S41431-018-0185-4  0.316
2018 Zlatar ZZ, Muniz MC, Espinoza S, Gratianne R, Gollan TH, Galasko D, Salmon DP. Subjective Cognitive Decline, Objective Cognition, and Depression in Older Hispanics Screened for Memory Impairment. Journal of Alzheimer's Disease : Jad. PMID 29689718 DOI: 10.3233/Jad-170865  0.354
2018 Tulloch J, Leong L, Chen S, Keene CD, Millard SP, Shutes-David A, Lopez OL, Kofler J, Kaye JA, Woltjer R, Nelson PT, Neltner JH, Jicha GA, Galasko D, Masliah E, et al. APOE DNA methylation is altered in Lewy body dementia. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29544979 DOI: 10.1016/J.Jalz.2018.02.005  0.442
2018 Chhatwal JP, Schultz AP, Johnson KA, Hedden T, Jaimes S, Benzinger TLS, Jack C, Ances BM, Ringman JM, Marcus DS, Ghetti B, Farlow MR, Danek A, Levin J, Yakushev I, ... ... Galasko DR, et al. Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. Brain : a Journal of Neurology. PMID 29522171 DOI: 10.1093/Brain/Awy053  0.425
2018 Wang LY, Raskind MA, Wilkinson CW, Shofer JB, Sikkema C, Szot P, Quinn JF, Galasko DR, Peskind ER. Associations between CSF cortisol and CSF norepinephrine in cognitively normal controls and patients with amnestic MCI and AD dementia. International Journal of Geriatric Psychiatry. PMID 29446123 DOI: 10.1002/gps.4856  0.504
2018 Groveman BR, Orrù CD, Hughson AG, Raymond LD, Zanusso G, Ghetti B, Campbell KJ, Safar J, Galasko D, Caughey B. Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC. Acta Neuropathologica Communications. 6: 7. PMID 29422107 DOI: 10.1186/s40478-018-0508-2  0.359
2018 Wang H, Stewart T, Toledo JB, Ginghina C, Tang L, Atik A, Aro P, Shaw LM, Trojanowski JQ, Galasko DR, Edland S, Jensen PH, Shi M, Zhang J. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease : Jad. 61: 1541-1553. PMID 29376878 DOI: 10.3233/Jad-171013  0.482
2018 Sundermann EE, Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Rubin LH, Bondi MW. Sex Influences the Accuracy of Subjective Memory Complaint Reporting in Older Adults. Journal of Alzheimer's Disease : Jad. 61: 1163-1178. PMID 29332038 DOI: 10.3233/Jad-170425  0.381
2018 Edmonds EC, Ard MC, Edland SD, Galasko DR, Salmon DP, Bondi MW. Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimer's & Dementia (New York, N. Y.). 4: 11-18. PMID 29296659 DOI: 10.1016/J.Trci.2017.11.001  0.38
2018 Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme T, Eicher JD, Shepherd CE, Parkkinen L, Darwent L, Heckman MG, Scholz SW, Troncoso JC, Pletnikova O, Ansorge O, Clarimon J, ... ... Galasko D, et al. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. The Lancet. Neurology. 17: 64-74. PMID 29263008 DOI: 10.1016/S1474-4422(17)30400-3  0.416
2017 Jacobs DM, Ard MC, Salmon DP, Galasko DR, Bondi MW, Edland SD. Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimer's & Dementia (New York, N. Y.). 3: 531-535. PMID 29124111 DOI: 10.1016/J.Trci.2017.08.010  0.335
2017 Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Shaw LM, Trojanowski JQ, Singleton A, Frasier M, Marek K, Galasko D. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology. PMID 29030452 DOI: 10.1212/Wnl.0000000000004609  0.335
2017 Reas ET, Hagler DJ, White NS, Kuperman JM, Bartsch H, Cross K, Loi RQ, Balachandra AR, Meloy MJ, Wierenga CE, Galasko D, Brewer JB, Dale AM, McEvoy LK. Sensitivity of restriction spectrum imaging to memory and neuropathology in Alzheimer's disease. Alzheimer's Research & Therapy. 9: 55. PMID 28764771 DOI: 10.1186/S13195-017-0281-7  0.426
2017 Mollenhauer B, Batrla R, El-Agnaf O, Galasko DR, Lashuel HA, Merchant KM, Shaw LM, Selkoe DJ, Umek R, Vanderstichele H, Zetterberg H, Zhang J, Caspell-Garcia C, Coffey C, Hutten SJ, et al. A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28734051 DOI: 10.1002/Mds.27090  0.338
2017 Saugstad JA, Lusardi TA, Van Keuren-Jensen KR, Phillips JI, Lind B, Harrington CA, McFarland TJ, Courtright AL, Reiman RA, Yeri AS, Kalani MYS, Adelson PD, Arango J, Nolan JP, Duggan E, ... ... Galasko DR, et al. Analysis of extracellular RNA in cerebrospinal fluid. Journal of Extracellular Vesicles. 6: 1317577. PMID 28717417 DOI: 10.1080/20013078.2017.1317577  0.32
2017 Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, Martin ER, Grenier-Boley B, Heilmann-Heimbach S, Chouraki V, Kuzma AB, ... ... Galasko DR, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics. PMID 28714976 DOI: 10.1038/Ng.3916  0.373
2017 Li G, Shofer JB, Petrie EC, Yu CE, Wilkinson CW, Figlewicz DP, Shutes-David A, Zhang J, Montine TJ, Raskind MA, Quinn JF, Galasko DR, Peskind ER. Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults. Alzheimer's Research & Therapy. 9: 48. PMID 28673336 DOI: 10.1186/S13195-017-0271-9  0.476
2017 McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, ... ... Galasko D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. PMID 28592453 DOI: 10.1212/Wnl.0000000000004058  0.405
2017 Müller S, Preische O, Sohrabi HR, Gräber S, Jucker M, Dietzsch J, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Graff-Radford NR, Levin J, Galasko D, et al. Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. Scientific Reports. 7: 1225. PMID 28450713 DOI: 10.1038/S41598-017-01327-W  0.383
2017 Xiao MF, Xu D, Craig MT, Pelkey KA, Chien CC, Shi Y, Zhang J, Resnick S, Pletnikova O, Salmon D, Brewer J, Edland S, Wegiel J, Tycko B, Savonenko A, ... ... Galasko D, et al. NPTX2 and cognitive dysfunction in Alzheimer's Disease. Elife. 6. PMID 28440221 DOI: 10.7554/Elife.23798  0.426
2017 Sengupta U, Portelius E, Hansson O, Farmer K, Castillo-Carranza D, Woltjer R, Zetterberg H, Galasko D, Blennow K, Kayed R. Tau oligomers in cerebrospinal fluid in Alzheimer's disease. Annals of Clinical and Translational Neurology. 4: 226-235. PMID 28382304 DOI: 10.1002/Acn3.382  0.512
2017 Zlatar ZZ, Muniz M, Galasko D, Salmon DP. Subjective Cognitive Decline Correlates With Depression Symptoms and Not With Concurrent Objective Cognition in a Clinic-Based Sample of Older Adults. The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences. PMID 28329816 DOI: 10.1093/Geronb/Gbw207  0.327
2017 Pottiez G, Yang L, Stewart T, Song N, Aro P, Galasko D, Quinn J, Peskind E, Shi M, Zhang J. A mass spectrometry-based method to quantify in parallel Tau and amyloid β 1-42 in CSF for the diagnostic of Alzheimer's Disease. Journal of Proteome Research. PMID 28112948 DOI: 10.1021/Acs.Jproteome.6B00829  0.487
2017 Xiao M, Xu D, Craig MT, Pelkey KA, Chien C, Shi Y, Zhang J, Resnick S, Pletnikova O, Salmon D, Brewer J, Edland S, Wegiel J, Tycko B, Savonenko A, ... ... Galasko D, et al. Author response: NPTX2 and cognitive dysfunction in Alzheimer’s Disease Elife. DOI: 10.7554/Elife.23798.027  0.376
2017 Galasko DR, Xiao M, Xu D, Zhang J, Craig MT, Pelkey K, Resnick SM, Troncoso JC, Reeves R, McBain C, Salmon DP, Brewer JB, Edland SD, Worley PF. NEURONAL PENTRAXIN 2 (NPTX2): A SYNAPTIC BIOMARKER OF COGNITIVE DYSFUNCTION IN ALZHEIMER’S DISEASE Alzheimer's & Dementia. 13: P1231-P1232. DOI: 10.1016/J.Jalz.2017.07.429  0.345
2017 Salmon DP, Heindel WC, Galasko DR, Hansen LA. [P3-454]: DEVELOPMENT OF THE NON-DECLARATIVE MEMORY PRIMING DEFICIT OVER THE COURSE OF ALZHEIMER's DISEASE Alzheimer's & Dementia. 13: P1146-P1146. DOI: 10.1016/J.Jalz.2017.06.1672  0.383
2016 Adamowicz DH, Roy S, Salmon DP, Galasko DR, Hansen LA, Masliah E, Gage FH. Hippocampal α-Synuclein in Dementia with Lewy Bodies Contributes to Memory Impairment and is Consistent with Spread of Pathology. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 28039370 DOI: 10.1523/Jneurosci.3047-16.2016  0.322
2016 Cronin P, McCarthy MJ, Lim AS, Salmon DP, Galasko D, Masliah E, De Jager PL, Bennett DA, Desplats P. Circadian alterations during early stages of Alzheimer's disease are associated with aberrant cycles of DNA methylation in BMAL1. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 27883893 DOI: 10.1016/J.Jalz.2016.10.003  0.433
2016 Kun-Rodrigues C, Ross OA, Orme T, Shepherd C, Parkkinen L, Darwent L, Hernandez D, Ansorge O, Clark LN, Honig LS, Marder K, Lemstra A, Scheltens P, van der Flier W, Louwersheimer E, ... ... Galasko D, et al. Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging. PMID 27666590 DOI: 10.1016/J.Neurobiolaging.2016.08.023  0.408
2016 Boeve BF, Dickson DW, Duda JE, Ferman TJ, Galasko DR, Galvin JE, Goldman JG, Growdon JH, Hurtig HI, Kaufer DI, Kantarci K, Leverenz JB, Lippa CF, Lopez OL, McKeith IG, et al. Arguing against the proposed definition changes of PD. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 27492190 DOI: 10.1002/Mds.26721  0.381
2016 Peavy GM, Edland SD, Toole BM, Hansen LA, Galasko DR, Mayo AM. Phenotypic differences based on staging of Alzheimer's neuropathology in autopsy-confirmed dementia with Lewy bodies. Parkinsonism & Related Disorders. PMID 27475955 DOI: 10.1016/J.Parkreldis.2016.07.008  0.51
2016 Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, Masliah E, Rissman RA. Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimer's & Dementia (Amsterdam, Netherlands). 3: 63-72. PMID 27408937 DOI: 10.1016/J.Jalz.2016.06.953  0.468
2016 Shi M, Kovac A, Korff A, Cook TJ, Ginghina C, Bullock KM, Yang L, Stewart T, Zheng D, Aro P, Atik A, Kerr KF, Zabetian CP, Peskind ER, Hu SC, ... ... Galasko DR, et al. CNS tau efflux via exosomes is likely increased in Parkinson disease but not in Alzheimer disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 27234211 DOI: 10.1016/J.Jalz.2016.04.003  0.441
2016 Mitolo M, Hamilton JM, Landy KM, Hansen LA, Galasko D, Pazzaglia F, Salmon DP. Visual Perceptual Organization Ability in Autopsy-Verified Dementia with Lewy Bodies and Alzheimer's Disease. Journal of the International Neuropsychological Society : Jins. 1-11. PMID 27221597 DOI: 10.1017/S1355617716000436  0.447
2016 Edmonds EC, Delano-Wood L, Jak AJ, Galasko DR, Salmon DP, Bondi MW. "Missed" Mild Cognitive Impairment: High False-Negative Error Rate Based on Conventional Diagnostic Criteria. Journal of Alzheimer's Disease : Jad. PMID 27031477 DOI: 10.3233/Jad-150986  0.403
2016 Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathologica. PMID 27021906 DOI: 10.1007/S00401-016-1552-2  0.383
2016 Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, et al. Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. Plos One. 11: e0152082. PMID 27010959 DOI: 10.1371/Journal.Pone.0152082  0.382
2016 Schott JM, Crutch SJ, Carrasquillo MM, Uphill J, Shakespeare TJ, Ryan NS, Yong KX, Lehmann M, Ertekin-Taner N, Graff-Radford NR, Boeve BF, Murray ME, Khan QU, Petersen RC, Dickson DW, ... ... Galasko D, et al. Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 26993346 DOI: 10.1016/J.Jalz.2016.01.010  0.428
2015 Landy KM, Salmon DP, Filoteo JV, Heindel WC, Galasko D, Hamilton JM. Visual search in Dementia with Lewy Bodies and Alzheimer's disease. Cortex; a Journal Devoted to the Study of the Nervous System and Behavior. 73: 228-239. PMID 26476402 DOI: 10.1016/J.Cortex.2015.08.020  0.394
2015 Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 47: 231-42. PMID 26402771 DOI: 10.3233/Jad-150128  0.502
2015 Li G, Xiong K, Korff A, Pan C, Quinn JF, Galasko DR, Liu C, Montine TJ, Peskind ER, Zhang J. Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF Aβ42 and Tau. Journal of Alzheimer's Disease : Jad. 47: 883-7. PMID 26401768 DOI: 10.3233/Jad-150420  0.476
2015 Landy KM, Salmon DP, Galasko D, Filoteo JV, Festa EK, Heindel WC, Hansen LA, Hamilton JM. Motion discrimination in dementia with Lewy bodies and Alzheimer disease. Neurology. PMID 26400581 DOI: 10.1212/Wnl.0000000000002028  0.439
2015 Salmon DP, Heindel WC, Hamilton JM, Vincent Filoteo J, Cidambi V, Hansen LA, Masliah E, Galasko D. Recognition memory span in autopsy-confirmed Dementia with Lewy Bodies and Alzheimer's Disease. Neuropsychologia. 75: 548-55. PMID 26184443 DOI: 10.1016/J.Neuropsychologia.2015.07.014  0.328
2015 Yang Y, Keene CD, Peskind ER, Galasko DR, Hu SC, Cudaback E, Wilson AM, Li G, Yu CE, Montine KS, Zhang J, Baird GS, Hyman BT, Montine TJ. Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease. Journal of Neuropathology and Experimental Neurology. 74: 672-87. PMID 26083568 DOI: 10.1097/Nen.0000000000000207  0.425
2015 Gordon MF, Lenderking WR, Duhig A, Chandler J, Lundy JJ, Miller DS, Piault-Louis E, Doody RS, Galasko D, Gauthier S, Frank L. Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 26079412 DOI: 10.1016/J.Jalz.2015.04.008  0.416
2015 Nation DA, Edmonds EC, Bangen KJ, Delano-Wood L, Scanlon BK, Han SD, Edland SD, Salmon DP, Galasko DR, Bondi MW. Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. Jama Neurology. 72: 546-53. PMID 25822631 DOI: 10.1001/Jamaneurol.2014.4477  0.355
2015 Pan C, Korff A, Galasko D, Ginghina C, Peskind E, Li G, Quinn J, Montine TJ, Cain K, Shi M, Zhang J. Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 45: 709-19. PMID 25613100 DOI: 10.3233/Jad-143099  0.45
2015 Shi M, Movius J, Dator R, Aro P, Zhao Y, Pan C, Lin X, Bammler TK, Stewart T, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Zhang J. Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. Molecular & Cellular Proteomics : McP. 14: 544-55. PMID 25556233 DOI: 10.1074/Mcp.M114.040576  0.354
2015 Wang LS, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JD, Cannon-Albright L, Baldwin CT, Zetterberg H, Blennow K, Kukull WA, Faber KM, Schupf N, Norton MC, ... ... Galasko DR, et al. Rarity of the Alzheimer disease-protective APP A673T variant in the United States. Jama Neurology. 72: 209-16. PMID 25531812 DOI: 10.1001/Jamaneurol.2014.2157  0.469
2015 Mackin RS, Insel P, Zhang J, Mohlenhoff B, Galasko D, Weiner M, Mattsson N. Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 43: 1007-16. PMID 25125463 DOI: 10.3233/Jad-141287  0.47
2015 Bangen KJ, Nation DA, Delano-Wood L, Weissberger GH, Hansen LA, Galasko DR, Salmon DP, Bondi MW. Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 394-403.e1. PMID 25022538 DOI: 10.1016/J.Jalz.2013.12.025  0.406
2015 Edmonds EC, Delano-Wood L, Clark LR, Jak AJ, Nation DA, McDonald CR, Libon DJ, Au R, Galasko D, Salmon DP, Bondi MW. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 415-24. PMID 24857234 DOI: 10.1016/J.Jalz.2014.03.005  0.45
2015 MacKin RS, Insel P, Zhang J, Mohlenhoff B, Galasko D, Weiner M, Mattsson N. Cerebrospinal fluid α-synuclein and lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease Journal of Alzheimer's Disease. 43: 1007-1016. DOI: 10.3233/JAD-141287  0.316
2015 Salmon DP, Heindel WC, Hamilton JM, Vincent Filoteo J, Cidambi V, Hansen LA, Masliah E, Galasko D. Recognition memory span in autopsy-confirmed Dementia with Lewy Bodies and Alzheimer's Disease Neuropsychologia. 75: 548-555. DOI: 10.1016/j.neuropsychologia.2015.07.014  0.329
2014 Donohue MC, Moghadam SH, Roe AD, Sun CK, Edland SD, Thomas RG, Petersen RC, Sano M, Galasko D, Aisen PS, Rissman RA. Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 25301682 DOI: 10.1016/J.Jalz.2014.07.156  0.419
2014 Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, Beecham GW, Rajbhandary RA, Hamilton-Nelson KL, Wang LS, Kauwe JS, Huentelman MJ, Myers AJ, Bird TD, Boeve BF, ... ... Galasko DR, et al. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. Jama Neurology. 71: 1394-404. PMID 25199842 DOI: 10.1001/Jamaneurol.2014.1491  0.371
2014 Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. Journal of the International Neuropsychological Society : Jins. 20: 836-47. PMID 25156329 DOI: 10.1017/S135561771400068X  0.429
2014 Pan C, Zhou Y, Dator R, Ginghina C, Zhao Y, Movius J, Peskind E, Zabetian CP, Quinn J, Galasko D, Stewart T, Shi M, Zhang J. Targeted discovery and validation of plasma biomarkers of Parkinson's disease. Journal of Proteome Research. 13: 4535-45. PMID 24853996 DOI: 10.1021/Pr500421V  0.318
2014 Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, ... Galasko D, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. The Lancet. Neurology. 13: 614-29. PMID 24849862 DOI: 10.1016/S1474-4422(14)70090-0  0.5
2014 Bondi MW, Edmonds EC, Jak AJ, Clark LR, Delano-Wood L, McDonald CR, Nation DA, Libon DJ, Au R, Galasko D, Salmon DP. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. Journal of Alzheimer's Disease : Jad. 42: 275-89. PMID 24844687 DOI: 10.3233/Jad-140276  0.474
2014 Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Galasko D, Schneider LS, Aisen PS. Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. Journal of the American Geriatrics Society. 62: 985-8. PMID 24828933 DOI: 10.1111/Jgs.12816  0.374
2014 Li G, Millard SP, Peskind ER, Zhang J, Yu CE, Leverenz JB, Mayer C, Shofer JS, Raskind MA, Quinn JF, Galasko DR, Montine TJ. Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. Jama Neurology. 71: 742-51. PMID 24756381 DOI: 10.1001/Jamaneurol.2014.445  0.42
2014 Siderowf A, Pontecorvo MJ, Shill HA, Mintun MA, Arora A, Joshi AD, Lu M, Adler CH, Galasko D, Liebsack C, Skovronsky DM, Sabbagh MN. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. Bmc Neurology. 14: 79. PMID 24716655 DOI: 10.1186/1471-2377-14-79  0.46
2014 Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen PS. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology. 82: 1536-42. PMID 24696507 DOI: 10.1212/Wnl.0000000000000364  0.426
2014 Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC, Al-Sarraj S, Neumann M, Gelpi E, Ghetti B, Rohrer JD, Halliday G, Van Broeckhoven C, Seilhean D, Shaw PJ, ... ... Galasko D, et al. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica. 127: 407-18. PMID 24442578 DOI: 10.1007/S00401-013-1239-X  0.327
2014 Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. Bmc Neurology. 14: 12. PMID 24423155 DOI: 10.1186/1471-2377-14-12  0.361
2014 Mitolo M, Salmon DP, Gardini S, Galasko D, Grossi E, Caffarra P. The new Qualitative Scoring MMSE Pentagon Test (QSPT) as a valid screening tool between autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 39: 823-32. PMID 24284368 DOI: 10.3233/JAD-131403  0.496
2014 Lineweaver TT, Bondi MW, Galasko D, Salmon DP. Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. The American Journal of Psychiatry. 171: 201-8. PMID 24170170 DOI: 10.1176/Appi.Ajp.2013.12121590  0.339
2014 Millard SP, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang D, Yu CE, Peskind ER, Bekris LM. Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects. Neurobiology of Aging. 35: 357-64. PMID 24011543 DOI: 10.1016/J.Neurobiolaging.2013.07.027  0.458
2014 Hamilton JM, Salmon DP, Raman R, Hansen LA, Masliah E, Peavy GM, Galasko D. Accounting for functional loss in Alzheimer's disease and dementia with Lewy bodies: beyond cognition. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 171-8. PMID 23850331 DOI: 10.1016/J.Jalz.2013.04.003  0.438
2014 Bondi M, Edmonds E, Jak A, Clark LR, Delano-Wood L, McDonald C, Nation DA, Libon D, Au R, Galasko D, Salmon D. P2-237: NEUROPSYCHOLOGICAL CRITERIA FOR MCI IMPROVES DIAGNOSTIC PRECISION, CSF BIOMARKER ASSOCIATIONS, AND PROGRESSION RATES Alzheimer's & Dementia. 10: P562-P563. DOI: 10.1016/J.Jalz.2014.05.914  0.355
2014 Nation DA, Delano-Wood L, Bangen KJ, Edmonds EC, Han D, Libon DJ, Salmon DP, Galasko DR, Bondi MW. P2-089: PULSE PRESSURE IS ASSOCIATED WITH AD BIOMARKERS Alzheimer's & Dementia. 10: P503-P503. DOI: 10.1016/J.Jalz.2014.05.763  0.35
2013 Mattsson N, Insel P, Tosun D, Zhang J, Jack CR, Galasko D, Weiner M. Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease. Plos One. 8: e85443. PMID 24392009 DOI: 10.1371/Journal.Pone.0085443  0.49
2013 Nation DA, Edland SD, Bondi MW, Salmon DP, Delano-Wood L, Peskind ER, Quinn JF, Galasko DR. Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology. 81: 2024-7. PMID 24225352 DOI: 10.1212/01.Wnl.0000436935.47657.78  0.379
2013 Olichney JM, Pak J, Salmon DP, Yang JC, Gahagan T, Nowacki R, Hansen L, Galasko D, Kutas M, Iragui-Madoz VJ. Abnormal P600 word repetition effect in elderly persons with preclinical Alzheimer's disease. Cognitive Neuroscience. 4: 143-51. PMID 24090465 DOI: 10.1080/17588928.2013.838945  0.467
2013 Pirogovsky E, Holden HM, Jenkins C, Peavy GM, Salmon DP, Galasko DR, Gilbert PE. Temporal sequence learning in healthy aging and amnestic mild cognitive impairment. Experimental Aging Research. 39: 371-81. PMID 23875836 DOI: 10.1080/0361073X.2013.808122  0.309
2013 Wang LY, Murphy RR, Hanscom B, Li G, Millard SP, Petrie EC, Galasko DR, Sikkema C, Raskind MA, Wilkinson CW, Peskind ER. Cerebrospinal fluid norepinephrine and cognition in subjects across the adult age span. Neurobiology of Aging. 34: 2287-92. PMID 23639207 DOI: 10.1016/j.neurobiolaging.2013.04.007  0.357
2013 Lamarre AK, Rascovsky K, Bostrom A, Toofanian P, Wilkins S, Sha SJ, Perry DC, Miller ZA, Naasan G, Laforce R, Hagen J, Takada LT, Tartaglia MC, Kang G, Galasko D, et al. Interrater reliability of the new criteria for behavioral variant frontotemporal dementia. Neurology. 80: 1973-7. PMID 23635967 DOI: 10.1212/Wnl.0B013E318293E368  0.41
2013 Peavy GM, Salmon DP, Edland SD, Tam S, Hansen LA, Masliah E, Galasko D, Hamilton JM. Neuropsychiatric features of frontal lobe dysfunction in autopsy-confirmed patients with lewy bodies and "pure" Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 21: 509-19. PMID 23567425 DOI: 10.1016/J.Jagp.2012.10.022  0.499
2013 Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, ... ... Galasko D, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron. 78: 256-68. PMID 23562540 DOI: 10.1016/J.Neuron.2013.02.026  0.424
2013 Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Trojanowski JQ, Weintraub D, Chen-Plotkin AS, ... ... Galasko D, et al. APOE ε4 increases risk for dementia in pure synucleinopathies. Jama Neurology. 70: 223-8. PMID 23407718 DOI: 10.1001/Jamaneurol.2013.600  0.364
2013 Galasko DR, Aisen P. Antioxidants for Alzheimer disease-reply. Jama Neurology. 70: 270-1. PMID 23400724 DOI: 10.1001/Jamaneurol.2013.935  0.439
2013 Winchester J, Dick MB, Gillen D, Reed B, Miller B, Tinklenberg J, Mungas D, Chui H, Galasko D, Hewett L, Cotman CW. Walking stabilizes cognitive functioning in Alzheimer's disease (AD) across one year. Archives of Gerontology and Geriatrics. 56: 96-103. PMID 22959822 DOI: 10.1016/J.Archger.2012.06.016  0.432
2013 Ard MC, Galasko DR, Edland SD. Improved statistical power of Alzheimer clinical trials by item-response theory: proof of concept by application to the activities of daily living scale. Alzheimer Disease and Associated Disorders. 27: 187-91. PMID 22874658 DOI: 10.1097/WAD.0b013e318265bcc1  0.422
2013 Sengupta U, Portelius E, Castillo-Carranza D, Woltjer R, Galasko D, Jackson G, Blennow K, Kayed R. P4-356: Tau oligomers in CSF: A novel biomarker for the diagnosis and evaluation of treatment for Alzheimer's disease and tauopathies Alzheimer's & Dementia. 9: P862-P863. DOI: 10.1016/J.Jalz.2013.08.190  0.409
2013 Ard MC, Galasko D, Salmon D, Edland S. P4-227: Assessing rates of cognitive decline in Alzheimer's disease and dementia with Lewy bodies Alzheimer's & Dementia. 9: P788-P788. DOI: 10.1016/J.Jalz.2013.05.1619  0.479
2012 Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Kukull W, Nelson PT, Jicha GA, ... ... Galasko D, et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology. 79: 1944-50. PMID 23035075 DOI: 10.1212/Wnl.0B013E3182735E9A  0.373
2012 Bekris LM, Millard S, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang DW, Yu CE, Peskind ER. Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 159: 874-83. PMID 22927204 DOI: 10.1002/Ajmg.B.32094  0.421
2012 Pillai JA, McEvoy LK, Hagler DJ, Holland D, Dale AM, Salmon DP, Galasko D, Fennema-Notestine C. Higher education is not associated with greater cortical thickness in brain areas related to literacy or intelligence in normal aging or mild cognitive impairment. Journal of Clinical and Experimental Neuropsychology. 34: 925-35. PMID 22905705 DOI: 10.1080/13803395.2012.702733  0.33
2012 Bekris LM, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang DW, Montine TJ, Peskind ER, Yu CE. ADAM10 expression and promoter haplotype in Alzheimer's disease. Neurobiology of Aging. 33: 2229.e1-2229.e9. PMID 22572541 DOI: 10.1016/J.Neurobiolaging.2012.03.013  0.419
2012 Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R, Lane JR, Karydas AM, Kenet RO, Biernat J, Wang LS, ... ... Galasko DR, et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Human Molecular Genetics. 21: 3500-12. PMID 22556362 DOI: 10.1093/Hmg/Dds161  0.437
2012 Nation DA, Delano-Wood L, Bangen KJ, Wierenga CE, Jak AJ, Hansen LA, Galasko DR, Salmon DP, Bondi MW. Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 30: 595-603. PMID 22451309 DOI: 10.3233/Jad-2012-111697  0.453
2012 Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Archives of Neurology. 69: 836-41. PMID 22431837 DOI: 10.1001/Archneurol.2012.85  0.404
2012 Irizarry MC, Jin S, He F, Emond JA, Raman R, Thomas RG, Sano M, Quinn JF, Tariot PN, Galasko DR, Ishihara LS, Weil JG, Aisen PS. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Archives of Neurology. 69: 368-72. PMID 22410444 DOI: 10.1001/Archneurol.2011.830  0.425
2012 Mandler M, Rockenstein E, Ubhi K, Hansen L, Adame A, Michael S, Galasko D, Santic R, Mattner F, Masliah E. Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AβPP transgenic mice using a novel monoclonal antibody. Journal of Alzheimer's Disease : Jad. 28: 783-94. PMID 22064070 DOI: 10.3233/Jad-2011-111208  0.439
2012 Peavy GM, Jacobson MW, Salmon DP, Gamst AC, Patterson TL, Goldman S, Mills PJ, Khandrika S, Galasko D. The influence of chronic stress on dementia-related diagnostic change in older adults. Alzheimer Disease and Associated Disorders. 26: 260-6. PMID 22037597 DOI: 10.1097/Wad.0B013E3182389A9C  0.432
2012 Hamilton JM, Landy KM, Salmon DP, Hansen LA, Masliah E, Galasko D. Early visuospatial deficits predict the occurrence of visual hallucinations in autopsy-confirmed dementia with Lewy bodies. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 20: 773-81. PMID 21997600 DOI: 10.1097/Jgp.0B013E31823033Bc  0.472
2012 Pillai J, Edland S, Gahagan T, Salmon D, Galasko D. Clinical and Neuropsychological Features of Pure and Mixed Hippocampal Sclerosis Dementia (P05.039) Neurology. 78: P05.039-P05.039. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P05.039  0.518
2012 Quinn J, Shinto L, Yurko-Mauro K, Galasko D, Aisen P, Montine T. P3-368: Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease Alzheimer's & Dementia. 8: P585-P585. DOI: 10.1016/J.Jalz.2012.05.1593  0.362
2011 Gollan TH, Salmon DP, Montoya RI, Galasko DR. Degree of bilingualism predicts age of diagnosis of Alzheimer's disease in low-education but not in highly educated Hispanics. Neuropsychologia. 49: 3826-30. PMID 22001315 DOI: 10.1016/J.Neuropsychologia.2011.09.041  0.401
2011 Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, ... ... Galasko D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain : a Journal of Neurology. 134: 2456-77. PMID 21810890 DOI: 10.1093/Brain/Awr179  0.426
2011 Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 77: 556-63. PMID 21795660 DOI: 10.1212/Wnl.0B013E318228Bf11  0.452
2011 Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, ... ... Galasko D, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: 386-395.e6. PMID 21784349 DOI: 10.1016/J.Jalz.2011.05.2243  0.415
2011 Britschgi M, Rufibach K, Huang SL, Clark CM, Kaye JA, Li G, Peskind ER, Quinn JF, Galasko DR, Wyss-Coray T. Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. Molecular & Cellular Proteomics : McP. 10: M111.008862. PMID 21742799 DOI: 10.1074/Mcp.M111.008862  0.443
2011 Golde TE, Lamb BT, Galasko D. Right sizing funding for Alzheimer's disease. Alzheimer's Research & Therapy. 3: 17. PMID 21554753 DOI: 10.1186/Alzrt76  0.415
2011 Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Edwards KL, Snapinn KW, et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. The American Journal of Pathology. 178: 1509-16. PMID 21435440 DOI: 10.1016/J.Ajpath.2011.01.006  0.452
2011 Rafii M, Taylor C, Coutinho A, Kim K, Galasko D. Comparison of the memory performance index with standard neuropsychological measures of cognition American Journal of Alzheimer's Disease and Other Dementias. 26: 235-239. PMID 21406427 DOI: 10.1177/1533317511402316  0.726
2011 Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of Neurology. 69: 570-80. PMID 21400565 DOI: 10.1002/Ana.22311  0.359
2011 Chang YL, Bondi MW, McEvoy LK, Fennema-Notestine C, Salmon DP, Galasko D, Hagler DJ, Dale AM. Global clinical dementia rating of 0.5 in MCI masks variability related to level of function. Neurology. 76: 652-9. PMID 21321338 DOI: 10.1212/Wnl.0B013E31820Ce6A5  0.467
2011 Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. Plos One. 6: e16032. PMID 21264269 DOI: 10.1371/Journal.Pone.0016032  0.523
2011 Bekris LM, Galloway NM, Millard S, Lockhart D, Li G, Galasko DR, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Leverenz JB, Seubert P, Tsuang DW, Peskind ER, et al. Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease. Neurobiology of Aging. 32: 556.e13-23. PMID 21196064 DOI: 10.1016/J.Neurobiolaging.2010.10.020  0.454
2011 Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease Alzheimer Disease and Associated Disorders. 25: 206-212. PMID 21192237 DOI: 10.1097/Wad.0B013E318204B550  0.362
2011 Montine TJ, Peskind ER, Quinn JF, Wilson AM, Montine KS, Galasko D. Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromolecular Medicine. 13: 37-43. PMID 20632131 DOI: 10.1007/S12017-010-8126-6  0.438
2011 Kramer PL, Xu H, Woltjer RL, Westaway SK, Clark D, Erten-Lyons D, Kaye JA, Welsh-Bohmer KA, Troncoso JC, Markesbery WR, Petersen RC, Turner RS, Kukull WA, Bennett DA, Galasko D, et al. Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiology of Aging. 32: 2113-22. PMID 20452100 DOI: 10.1016/J.Neurobiolaging.2010.01.010  0.502
2011 Cruchaga C, Kauwe J, Mayo K, Bertelsen S, Hinrichs T, Peskind E, Li G, Leverenz J, Galasko D, Fagan A, Holtzman D, Goate A. Genome-Wide Association Analyses Using Cerebrospinal Fluid Tau and Phospho-Tau Levels As An Endophenotype for Alzheimer’s Disease Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.503  0.344
2011 Salmon DP, Masliah E, Galasko D, Peavy G, Hansen L, Hamilton J. P1-168: Behavioral abnormalities are associated with milder dementia in Alzheimer's disease than in dementia with lewy bodies Alzheimer's & Dementia. 7: S165-S166. DOI: 10.1016/J.Jalz.2011.05.447  0.468
2011 Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Xie S, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis A, Josephs KA, Boeve BF, Kertesz A, Seeley WW, ... ... Galasko D, et al. P4-166: Determinants of survival in autopsy-confirmed patients with behavioral variant frontotemporal dementia (bvFTD): Second Report of the international bvFTD criteria consortium (FTDC) Alzheimer's & Dementia. 7: S761-S762. DOI: 10.1016/J.Jalz.2011.05.2188  0.357
2010 Mortimer JA, Borenstein AR, Ding D, Decarli C, Zhao Q, Copenhaver C, Guo Q, Chu S, Galasko D, Salmon DP, Dai Q, Wu Y, Petersen R, Hong Z. High normal fasting blood glucose is associated with dementia in Chinese elderly. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 440-7. PMID 21044774 DOI: 10.1016/J.Jalz.2010.03.017  0.44
2010 Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biological Psychiatry. 68: 903-12. PMID 21035623 DOI: 10.1016/J.Biopsych.2010.08.025  0.521
2010 He J, Iosif AM, Lee DY, Martinez O, Chu S, Carmichael O, Mortimer JA, Zhao Q, Ding D, Guo Q, Galasko D, Salmon DP, Dai Q, Wu Y, Petersen RC, et al. Brain structure and cerebrovascular risk in cognitively impaired patients: Shanghai Community Brain Health Initiative-pilot phase. Archives of Neurology. 67: 1231-7. PMID 20937951 DOI: 10.1001/Archneurol.2010.230  0.4
2010 Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, et al. Revising the definition of Alzheimer's disease: a new lexicon. The Lancet. Neurology. 9: 1118-27. PMID 20934914 DOI: 10.1016/S1474-4422(10)70223-4  0.504
2010 Pedrosa H, De Sa A, Guerreiro M, Maroco J, Simoes MR, Galasko D, de Mendonca A. Functional evaluation distinguishes MCI patients from healthy elderly people--the ADCS/MCI/ADL scale. The Journal of Nutrition, Health & Aging. 14: 703-9. PMID 20922349 DOI: 10.1007/s12603-010-0102-1  0.392
2010 Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, Owen MM, Williams J, Lovestone S, Peskind ER, Li G, ... ... Galasko D, et al. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. Plos Genetics. 6: e1001101. PMID 20862329 DOI: 10.1371/Journal.Pgen.1001101  0.46
2010 Ubhi K, Peng K, Lessig S, Estrella J, Adame A, Galasko D, Salmon DP, Hansen LA, Kawas CH, Masliah E. Neuropathology of dementia with Lewy bodies in advanced age: a comparison with Alzheimer disease. Neuroscience Letters. 485: 222-7. PMID 20849919 DOI: 10.1016/J.Neulet.2010.09.016  0.485
2010 Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J. CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2682-5. PMID 20818673 DOI: 10.1002/Mds.23287  0.389
2010 Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. The Febs Journal. 277: 3051-67. PMID 20573181 DOI: 10.1111/J.1742-4658.2010.07719.X  0.405
2010 Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB, Zhang J. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neuroscience Letters. 480: 78-82. PMID 20540987 DOI: 10.1016/J.Neulet.2010.06.009  0.311
2010 Lessig S, Ubhi K, Galasko D, Adame A, Pham E, Remidios K, Chang M, Hansen LA, Masliah E. Reduced hypocretin (orexin) levels in dementia with Lewy bodies. Neuroreport. 21: 756-60. PMID 20531237 DOI: 10.1097/Wnr.0B013E32833Bfb7C  0.402
2010 Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, Hansen L, Adame A, Galasko D, Masliah E. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. Plos One. 5: e9313. PMID 20174468 DOI: 10.1371/Journal.Pone.0009313  0.355
2010 Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain : a Journal of Neurology. 133: 713-26. PMID 20157014 DOI: 10.1093/Brain/Awq008  0.339
2010 Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, Harmsen A, Gustavsson MK, Hanse E, Galasko D, Hampel H, Blennow K, Zetterberg H. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Molecular Neurodegeneration. 5: 2. PMID 20145736 DOI: 10.1186/1750-1326-5-2  0.368
2010 Borenstein AR, Mortimer JA, Ding Ding, Schellenberg GD, DeCarli C, Qianhua Zhao, Copenhaver C, Qihao Guo, Shugang Chu, Galasko D, Salmon DP, Qi Dai, Yougui Wu, Petersen R, Zhen Hong. Effects of apolipoprotein E-epsilon4 and -epsilon2 in amnestic mild cognitive impairment and dementia in Shanghai: SCOBHI-P. American Journal of Alzheimer's Disease and Other Dementias. 25: 233-8. PMID 20142627 DOI: 10.1177/1533317509357736  0.447
2010 Hong RZ, Borenstein AR, Mortimer JA, Ding D, Zhao Q, Guo Q, Galasko D, Salmon D, Petersen R. P4-142: Contact Factors Differ for Dementia and Amnestic MCI in Chinese Elders: The Pilot SCOBHI Study. Alzheimer's & Dementia. 6: e65-e65. DOI: 10.1016/J.Jalz.2010.08.201  0.382
2010 Bekris LM, Galloway N, Li G, Galasko DR, DeCarli C, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Leverenz JB, Seubert P, Tsuang DW, Peskind ER, Yu CE. P1-056: Genetic variation within APP processing genes correlates with cerebrospinal fluid APP cleavage product levels in Alzheimer patients and cognitively normal subjects Alzheimer's & Dementia. 6: S189-S190. DOI: 10.1016/J.Jalz.2010.05.604  0.39
2010 Edland SD, Peskind ER, Li G, Millard SP, Quinn JF, Clark CM, Galasko D. O4-06-07: CSF biomarkers for Alzheimer's disease are bimodal within cognitively normal elderly Alzheimer's & Dementia. 6: S161-S161. DOI: 10.1016/j.jalz.2010.05.502  0.448
2010 Craig-Schapiro R, Perrin RJ, Roe CM, Grant EA, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, et al. P3-190: A novel diagnostic and prognostic fluid biomarker for early Alzheimer's disease: YKL-40 Alzheimer's & Dementia. 6: S506-S506. DOI: 10.1016/J.Jalz.2010.05.1688  0.408
2010 Perrin RJ, Craig-Schapiro R, Malone JP, Roe CM, Grant EA, Shah AR, Gilmore P, Davis AE, Peskind ER, Li G, Galasko DR, Quinn JF, Kaye JA, Clark CM, Morris JC, et al. P3-172: Identification and validation of novel cerebrospinal fluid protein biomarkers for early Alzheimer's disease using proteomics and ELISA: a multi-institutional collaborative study Alzheimer's & Dementia. 6: S500-S500. DOI: 10.1016/J.Jalz.2010.05.1670  0.306
2010 Ubhi K, Peng KA, Lessig S, Estrella J, Adame A, Galasko D, Salmon DP, Hansen LA, Kawas CH, Masliah E. P2-117: Age, clinical indices and neuropathology in Alzheimer disease and dementia with lewy bodies Alzheimer's & Dementia. 6: S347-S348. DOI: 10.1016/J.Jalz.2010.05.1164  0.464
2009 Peavy GM, Salmon DP, Jacobson MW, Hervey A, Gamst AC, Wolfson T, Patterson TL, Goldman S, Mills PJ, Khandrika S, Galasko D. Effects of chronic stress on memory decline in cognitively normal and mildly impaired older adults. The American Journal of Psychiatry. 166: 1384-91. PMID 19755573 DOI: 10.1176/Appi.Ajp.2009.09040461  0.363
2009 Snyder LR, Cruz-Aguado R, Sadilek M, Galasko D, Shaw CA, Montine TJ. Parkinson-dementia complex and development of a new stable isotope dilution assay for BMAA detection in tissue. Toxicology and Applied Pharmacology. 240: 180-8. PMID 19716838 DOI: 10.1016/J.Taap.2009.06.025  0.36
2009 Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 106: 12145-50. PMID 19581601 DOI: 10.1073/Pnas.0904866106  0.361
2009 Sieh W, Choi Y, Chapman NH, Craig UK, Steinbart EJ, Rothstein JH, Oyanagi K, Garruto RM, Bird TD, Galasko DR, Schellenberg GD, Wijsman EM. Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. Human Molecular Genetics. 18: 3725-38. PMID 19567404 DOI: 10.1093/Hmg/Ddp300  0.322
2009 Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford NR, Chui H, Cummings J, DeCarli C, Foster NL, Galasko D, Peskind E, Dietrich W, Beekly DL, Kukull WA, Morris JC. The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Disease and Associated Disorders. 23: 91-101. PMID 19474567 DOI: 10.1097/Wad.0B013E318191C7Dd  0.455
2009 Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Archives of Neurology. 66: 632-7. PMID 19433663 DOI: 10.1001/Archneurol.2009.59  0.378
2009 Li G, Peskind ER, Millard SP, Chi P, Sokal I, Yu CE, Bekris LM, Raskind MA, Galasko DR, Montine TJ. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. Plos One. 4: e5424. PMID 19412541 DOI: 10.1371/Journal.Pone.0005424  0.436
2009 Ma QL, Galasko DR, Ringman JM, Vinters HV, Edland SD, Pomakian J, Ubeda OJ, Rosario ER, Teter B, Frautschy SA, Cole GM. Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid. Archives of Neurology. 66: 448-57. PMID 19364929 DOI: 10.1001/Archneurol.2009.22  0.435
2009 Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Annals of Clinical Biochemistry. 46: 235-40. PMID 19342441 DOI: 10.1258/Acb.2009.008232  0.377
2009 Filoteo JV, Salmon DP, Schiehser DM, Kane AE, Hamilton JM, Rilling LM, Lucas JA, Zizak V, Galasko DR. Verbal learning and memory in patients with dementia with Lewy bodies or Parkinson's disease with dementia. Journal of Clinical and Experimental Neuropsychology. 31: 823-34. PMID 19221922 DOI: 10.1080/13803390802572401  0.393
2009 Ding D, Zhao Q, Mortimer J, Copenhaver CI, Wu Y, Galasko D, Salmon D, Guo Q, DeCarli C, Dai Q, Petersen R, Hong Z, Borenstein AR. P1-207: Assessing quality of life by EQ-5D among Chinese elderly with cognitive function impairment: Findings from SCOBHI pilot Alzheimer's & Dementia. 5: P237-P238. DOI: 10.1016/J.Jalz.2009.04.214  0.31
2009 Peskind ER, Li GG, Millard S, Chi P, Sokal I, Yu C, Bekris L, Raskind MA, Galasko D, Montine TJ. P3-033: Age-related decline in cognitive function is associated with cerebrospinal fluid concentration of brain-derived neurotrophic factor Alzheimer's & Dementia. 5: P349-P350. DOI: 10.1016/J.Jalz.2009.04.1210  0.324
2009 Mortimer J, Borenstein A, Ding D, Copenhaver C, Wu Y, Galasko D, Salmon D, Zhao Q, Guo Q, DeCarli C, Dai Q, Petersen R, Hong Z. P3-119: Higher blood glucose is associated with dementia among Chinese elderly independent of vascular risk factors and white matter hyperintensity volume: findings from SCOBHI Alzheimer's & Dementia. 5: P379-P379. DOI: 10.1016/J.Jalz.2009.04.1094  0.307
2008 Hamilton JM, Salmon DP, Galasko D, Raman R, Emond J, Hansen LA, Masliah E, Thal LJ. Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies. Neuropsychology. 22: 729-37. PMID 18999346 DOI: 10.1037/A0012949  0.658
2008 Vuletic S, Li G, Peskind ER, Kennedy H, Marcovina SM, Leverenz JB, Petrie EC, Lee VM, Galasko D, Schellenberg GD, Albers JJ. Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid. Journal of Alzheimer's Disease : Jad. 15: 409-17. PMID 18997294 DOI: 10.3233/Jad-2008-15307  0.334
2008 Teng E, Ringman JM, Ross LK, Mulnard RA, Dick MB, Bartzokis G, Davies HD, Galasko D, Hewett L, Mungas D, Reed BR, Schneider LS, Segal-Gidan F, Yaffe K, Cummings JL, et al. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 16: 469-77. PMID 18515691 DOI: 10.1097/Jgp.0B013E318165Dbae  0.31
2008 Bekris LM, Millard SP, Galloway NM, Vuletic S, Albers JJ, Li G, Galasko DR, DeCarli C, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Tsuang D, Peskind ER, et al. Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. Journal of Alzheimer's Disease : Jad. 13: 255-66. PMID 18430993 DOI: 10.3233/Jad-2008-13303  0.406
2008 Rascovsky K, Salmon DP, Hansen LA, Galasko D. Distinct cognitive profiles and rates of decline on the Mattis Dementia Rating Scale in autopsy-confirmed frontotemporal dementia and Alzheimer's disease. Journal of the International Neuropsychological Society : Jins. 14: 373-83. PMID 18419836 DOI: 10.1017/S135561770808051X  0.513
2008 Rafii MS, Galasko D. Primary care screening for dementia and mild cognitive impairment. Jama. 299: 1132; author reply 1. PMID 18334686 DOI: 10.1001/jama.299.10.1132-a  0.704
2008 Leverenz JB, Hamilton R, Tsuang DW, Schantz A, Vavrek D, Larson EB, Kukull WA, Lopez O, Galasko D, Masliah E, Kaye J, Woltjer R, Clark C, Trojanowski JQ, Montine TJ. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathology (Zurich, Switzerland). 18: 220-4. PMID 18241240 DOI: 10.1111/J.1750-3639.2007.00117.X  0.403
2008 Geser F, Winton MJ, Kwong LK, Xu Y, Xie SX, Igaz LM, Garruto RM, Perl DP, Galasko D, Lee VM, Trojanowski JQ. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathologica. 115: 133-45. PMID 17713769 DOI: 10.1007/S00401-007-0257-Y  0.33
2008 Galasko D, Peskind E, Clark CM, Quinn J, Ringman J, Jicha GA, Cottrell B, Thomas RG. O2-04-06: Randomized clinical trial of antioxidant treatment in Alzheimer's disease with CSF biomarker measures Alzheimer's & Dementia. 4: T139-T139. DOI: 10.1016/J.Jalz.2008.05.336  0.376
2008 Sabbagh MN, Bell J, Agro A, Aisen P, Galasko D. P4-389: An oral antagonist of the receptor for advanced glycation end products (RAGE) is safe and well-tolerated in the treatment of Alzheimer's disease: Results from a phase II study Alzheimer's & Dementia. 4: T788-T788. DOI: 10.1016/J.Jalz.2008.05.2459  0.33
2008 Pham HE, Hansen L, Adame A, Salmon D, Galasko D, Glabe C, Masliah E. P4-279: Progressive accumulation of Abeta oligomers in the brains of patients with Alzheimer's disease is associated with selective alterations in synaptic proteins Alzheimer's & Dementia. 4: T753-T753. DOI: 10.1016/J.Jalz.2008.05.2348  0.387
2008 Raskind MA, Petrie EC, Wilkinson CW, Li G, Chi P, Galasko DR, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Wang LY, Leverenz JB, Schellenberg GD, Peskind ER. P3-090: Cerebrospinal fluid norepinephrine increases with aging, Alzheimers disease and APOE4 genotype Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.1654  0.404
2008 Perrin RJ, Malone JP, Shah AR, Craig-Schapiro R, Gilmore P, Davis AE, Peskind ER, Li G, Galasko DR, Quinn JF, Kaye JA, Clark CM, Morris JC, Holtzman DM, Townsend RR, et al. P3-088: Identification of potential biomarkers for Alzheimer's disease in cerebrospinal fluid using two-dimensional difference gel electrophoresis and tandem mass spectrometry: A multi-institutional collaborative study Alzheimer's & Dementia. 4: T543-T543. DOI: 10.1016/J.Jalz.2008.05.1652  0.373
2008 Li G, Galasko DR, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Raskind MA, Petrie EC, Leverenz J, Shofer JB, Schellenberg GD, Cottrell B, Peskind ER. P3-085: Age- and APOE-related cerebrospinal fluid Alzheimer's disease biomarker changes in normal controls Alzheimer's & Dementia. 4: T542-T543. DOI: 10.1016/J.Jalz.2008.05.1649  0.41
2008 Cole GM, Ma Q, Galasko DR, Ringman JM, Vinters HV, Ubeda OJ, Rosario ER, Frautschy SA. P3-064: Can SorLA/LR11, a sorting protein limiting Abeta production, serve as both therapeutic and diagnostic target in Alzheimer's disease? Alzheimer's & Dementia. 4: T536-T536. DOI: 10.1016/J.Jalz.2008.05.1628  0.379
2008 Salmon DP, Hamilton JM, Filoteo JV, Heindel WC, Galasko D. P2-216: Working memory deficits are greater in patients with autopsy-confirmed dementia with Lewy bodies (DLB) than in those with Alzheimer's disease (AD) Alzheimer's & Dementia. 4: T434-T435. DOI: 10.1016/J.Jalz.2008.05.1291  0.495
2007 Rascovsky K, Hodges JR, Kipps CM, Johnson JK, Seeley WW, Mendez MF, Knopman D, Kertesz A, Mesulam M, Salmon DP, Galasko D, Chow TW, Decarli C, Hillis A, Josephs K, et al. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Disease and Associated Disorders. 21: S14-8. PMID 18090417 DOI: 10.1097/Wad.0B013E31815C3445  0.367
2007 Mickes L, Wixted JT, Fennema-Notestine C, Galasko D, Bondi MW, Thal LJ, Salmon DP. Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer's disease. Neuropsychology. 21: 696-705. PMID 17983283 DOI: 10.1037/0894-4105.21.6.696  0.595
2007 Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Medicine. 13: 1359-62. PMID 17934472 DOI: 10.1038/Nm1653  0.452
2007 Yang W, Woltjer RL, Sokal I, Pan C, Wang Y, Brodey M, Peskind ER, Leverenz JB, Zhang J, Perl DP, Galasko DR, Montine TJ. Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy. The American Journal of Pathology. 171: 993-1002. PMID 17675576 DOI: 10.2353/Ajpath.2007.070015  0.484
2007 Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, Arnold SE, Siderowf A, Grossman M, Leverenz JB, Woltjer R, Lopez OL, Hamilton R, Tsuang DW, Galasko D, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathologica. 114: 221-9. PMID 17653732 DOI: 10.1007/S00401-007-0261-2  0.459
2007 Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. The Lancet. Neurology. 6: 734-46. PMID 17616482 DOI: 10.1016/S1474-4422(07)70178-3  0.47
2007 Galasko D, Salmon D, Gamst A, Olichney J, Thal LJ, Silbert L, Kaye J, Brooks P, Adonay R, Craig UK, Schellenberg G, Borenstein AR. Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE. Neurology. 68: 1772-81. PMID 17515539 DOI: 10.1212/01.Wnl.0000262028.16738.64  0.594
2007 Borenstein AR, Mortimer JA, Schofield E, Wu Y, Salmon DP, Gamst A, Olichney J, Thal LJ, Silbert L, Kaye J, Craig UL, Schellenberg GD, Galasko DR. Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam. Neurology. 68: 1764-71. PMID 17515538 DOI: 10.1212/01.Wnl.0000262027.31623.B2  0.538
2007 Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 68: 812-9. PMID 17353469 DOI: 10.1212/01.Wnl.0000256715.13907.D3  0.38
2007 Rascovsky K, Salmon DP, Hansen LA, Thal LJ, Galasko D. Disparate letter and semantic category fluency deficits in autopsy-confirmed frontotemporal dementia and Alzheimer's disease. Neuropsychology. 21: 20-30. PMID 17201527 DOI: 10.1037/0894-4105.21.1.20  0.626
2007 Craft S, Peskind E, Goldgaber D, Li G, Nie W, Galasko D, Leverenz J, Petrie E, Raskind M. P-027: CSF transthyretin levels are associated with APOE genotype and CSF aβ42 in AD Alzheimers & Dementia. 3. DOI: 10.1016/J.Jalz.2007.04.243  0.419
2006 Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers JJ, Montine TJ, Lee VM, Lee M, Seubert P, Galasko D, Schellenberg GD, Hazzard WR, Peskind ER. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. Journal of Alzheimer's Disease : Jad. 10: 399-406. PMID 17183151 DOI: 10.3233/Jad-2006-10408  0.443
2006 Galasko D, Bennett DA, Sano M, Marson D, Kaye J, Edland SD. ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Disease and Associated Disorders. 20: S152-69. PMID 17135809 DOI: 10.1097/01.Wad.0000213873.25053.2B  0.368
2006 Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal LJ. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Disease and Associated Disorders. 20: S109-23. PMID 17135805 DOI: 10.1097/01.Wad.0000213870.40300.21  0.578
2006 Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Disease and Associated Disorders. 20: 210-6. PMID 17132964 DOI: 10.1097/01.Wad.0000213865.09806.92  0.43
2006 Thal LJ, Kawas C, Galasko D, Salmon DP, Sundsmo MP. Robert Katzman honored. Alzheimer Disease and Associated Disorders. 20: S27-8. PMID 16917190 DOI: 10.1097/00002093-200607001-00001  0.41
2006 Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Raskind MA, Schellenberg GD, Lee VM, Galasko DR. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Archives of Neurology. 63: 936-9. PMID 16831961 DOI: 10.1001/Archneur.63.7.936  0.35
2006 Winton MJ, Joyce S, Zhukareva V, Practico D, Perl DP, Galasko D, Craig U, Trojanowski JQ, Lee VM. Characterization of tau pathologies in gray and white matter of Guam parkinsonism-dementia complex. Acta Neuropathologica. 111: 401-12. PMID 16609851 DOI: 10.1007/S00401-006-0053-0  0.416
2006 Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Praticò D, Griffin S, Schenk D, Siemers E. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Disease and Associated Disorders. 20: 6-15. PMID 16493230 DOI: 10.1097/01.Wad.0000191420.61260.A8  0.618
2006 Janvin CC, Larsen JP, Salmon DP, Galasko D, Hugdahl K, Aarsland D. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 337-42. PMID 16211595 DOI: 10.1002/mds.20726  0.52
2006 Peskind ER, Li G, Shofer J, Quinn J, Kaye J, Clark CM, Farlow M, DeCarli C, Raskind MA, Schellenberg GD, Lee VM, Galasko D. P2-134: Age and apolipoprotein E*4 effects on cerebrospinal fluid Aβ42 in cognitively normal adults Alzheimer's & Dementia. 2: S273-S273. DOI: 10.1016/J.Jalz.2006.05.972  0.372
2006 Galasko D, Salmon D, Olichney J, Thal LJ, Gamst A, Silbert L, Kaye J, Borenstein A, Schellenberg G, Brooks P, Adonay R, Craig U. P3-147: The prevalence of dementia among elderly chamorros on guam and lack of association with the APO e4 allele Alzheimer's & Dementia. 2: S417-S417. DOI: 10.1016/J.Jalz.2006.05.1415  0.551
2005 Peskind ER, Riekse R, Quinn JF, Kaye J, Clark CM, Farlow MR, Decarli C, Chabal C, Vavrek D, Raskind MA, Galasko D. Safety and acceptability of the research lumbar puncture. Alzheimer Disease and Associated Disorders. 19: 220-5. PMID 16327349 DOI: 10.1097/01.Wad.0000194014.43575.Fd  0.398
2005 McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, ... ... Galasko D, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 65: 1863-72. PMID 16237129 DOI: 10.1212/01.Wnl.0000187889.17253.B1  0.412
2005 Galasko D, Schmitt F, Thomas R, Jin S, Bennett D. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. Journal of the International Neuropsychological Society : Jins. 11: 446-53. PMID 16209425 DOI: 10.1017/S1355617705050502  0.514
2005 Wiltfang J, Lewczuk P, Riederer P, Grünblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselmann H, Henkel AW, Kornhuber J, et al. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 6: 69-84. PMID 16156480 DOI: 10.1080/15622970510029786  0.475
2005 Rascovsky K, Salmon DP, Lipton AM, Leverenz JB, DeCarli C, Jagust WJ, Clark CM, Mendez MF, Tang-Wai DF, Graff-Radford NR, Galasko D. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology. 65: 397-403. PMID 16087904 DOI: 10.1212/01.Wnl.0000171343.43314.6E  0.523
2005 Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Vitamin E and donepezil for the treatment of mild cognitive impairment. The New England Journal of Medicine. 352: 2379-88. PMID 15829527 DOI: 10.1056/Nejmoa050151  0.62
2005 Thal LJ, Thomas RG, Grundman M, Bennett DA, Doody RS, Ferris SH, Galasko DR, Jin S, Levey AI, Petersen RC. [O2-01-01]: Donepezil and vitamin E in the progression of mild cognitive impairment to Alzheimer's disease: A hazard-ratio analysis Alzheimer's & Dementia. 1: S93-S94. DOI: 10.1016/J.Jalz.2005.06.326  0.584
2004 Hamilton JM, Salmon DP, Galasko D, Delis DC, Hansen LA, Masliah E, Thomas RG, Thal LJ. A comparison of episodic memory deficits in neuropathologically-confirmed Dementia with Lewy bodies and Alzheimer's disease. Journal of the International Neuropsychological Society : Jins. 10: 689-97. PMID 15327716 DOI: 10.1017/S1355617704105043  0.618
2004 Galasko D, Kershaw PR, Schneider L, Zhu Y, Tariot PN. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease Journal of the American Geriatrics Society. 52: 1070-1076. PMID 15209643 DOI: 10.1111/j.1532-5415.2004.52303.x  0.488
2004 Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Archives of Neurology. 61: 59-66. PMID 14732621 DOI: 10.1001/Archneur.61.1.59  0.642
2004 Rascovsky K, Salmon DP, Galasko D, Hansen LA, Thal LJ. P3-344 Differential contributions of cognitive and behavioral deficits to functional impairment in FTD and AD Neurobiology of Aging. 25: S453. DOI: 10.1016/S0197-4580(04)81493-3  0.585
2004 Hamilton JM, Salmon DP, Galasko D, Hansen LA, Thal LJ. O4-06-05 Differential prediction of global cognitive decline in autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease Neurobiology of Aging. 25: S86. DOI: 10.1016/S0197-4580(04)80292-6  0.612
2003 Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Archives of Neurology. 60: 1696-702. PMID 14676043 DOI: 10.1001/Archneur.60.12.1696  0.504
2003 Caligiuri MP, Peavy G, Salmon DP, Galasko DR, Thal LJ. Neuromotor abnormalities and risk for psychosis in Alzheimer's disease. Neurology. 61: 954-8. PMID 14557567 DOI: 10.1212/01.Wnl.0000086823.08213.De  0.611
2003 Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: Comparison with progressive supranuclear palsy and Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry. 74: 1215-1220. PMID 12933921 DOI: 10.1136/Jnnp.74.9.1215  0.518
2003 Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, Thal LJ, Corey-Bloom J. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 60: 1586-90. PMID 12771246 DOI: 10.1212/01.Wnl.0000065889.42856.F2  0.719
2003 Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, Rogers J, Siemers E, Trojanowski JQ. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiology of Aging. 24: 521-36. PMID 12714109 DOI: 10.1016/S0197-4580(03)00002-2  0.428
2003 Granholm E, Morris S, Galasko D, Shults C, Rogers E, Vukov B. Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease. International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology. 47: 95-115. PMID 12568941 DOI: 10.1016/S0167-8760(02)00122-8  0.432
2002 Lange KL, Bondi MW, Salmon DP, Galasko D, Delis DC, Thomas RG, Thal LJ. Decline in verbal memory during preclinical Alzheimer's disease: examination of the effect of APOE genotype. Journal of the International Neuropsychological Society : Jins. 8: 943-55. PMID 12405546 DOI: 10.1017/S1355617702870096  0.59
2002 Ho GJ, Hansen LA, Alford MF, Foster K, Salmon DP, Galasko D, Thal LJ, Masliah E. Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease. Neuroreport. 13: 1825-8. PMID 12395133 DOI: 10.1097/00001756-200210070-00028  0.647
2002 Teter B, Xu PT, Gilbert JR, Roses AD, Galasko D, Cole GM. Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function. Journal of Neuroscience Research. 68: 331-6. PMID 12111863 DOI: 10.1002/jnr.10221  0.361
2002 Rascovsky K, Salmon DP, Ho GJ, Galasko D, Peavy GM, Hansen LA, Thal LJ. Cognitive profiles differ in autopsy-confirmed frontotemporal dementia and AD. Neurology. 58: 1801-8. PMID 12084880 DOI: 10.1212/Wnl.58.12.1801  0.631
2002 Weiner MF, Tractenberg RE, Sano M, Logsdon R, Teri L, Galasko D, Gamst A, Thomas R, Thal LJ. No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients. Journal of Geriatric Psychiatry and Neurology. 15: 95-8. PMID 12083600 DOI: 10.1177/089198870201500208  0.554
2002 Galasko D, Marder K. Picking away at frontotemporal dementia. Neurology. 58: 1585-6. PMID 12058081 DOI: 10.1212/Wnl.58.11.1585  0.418
2002 Haan MN, Jagust WJ, Galasko D, Kaye J. Effect of extrapyramidal signs and Lewy bodies on survival in patients with Alzheimer disease. Archives of Neurology. 59: 588-93. PMID 11939893 DOI: 10.1001/Archneur.59.4.588  0.5
2002 Galasko D, Salmon DP, Craig UK, Thal LJ, Schellenberg G, Wiederholt W. Clinical features and changing patterns of neurodegenerative disorders on Guam, 1997-2000. Neurology. 58: 90-7. PMID 11781411 DOI: 10.1212/Wnl.58.1.90  0.609
2001 Masliah E, Alford M, Galasko D, Salmon D, Hansen LA, Good PF, Perl DP, Thal L. Cholinergic deficits in the brains of patients with parkinsonism-dementia complex of Guam. Neuroreport. 12: 3901-3. PMID 11742207 DOI: 10.1097/00001756-200112210-00009  0.594
2001 Poorkaj P, Tsuang D, Wijsman E, Steinbart E, Garruto RM, Craig UK, Chapman NH, Anderson L, Bird TD, Plato CC, Perl DP, Weiderholt W, Galasko D, Schellenberg GD. TAU as a susceptibility gene for amyotropic lateral sclerosis-parkinsonism dementia complex of Guam. Archives of Neurology. 58: 1871-8. PMID 11708997 DOI: 10.1001/Archneur.58.11.1871  0.318
2001 Rockenstein E, Hansen LA, Mallory M, Trojanowski JQ, Galasko D, Masliah E. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Research. 914: 48-56. PMID 11578596 DOI: 10.1016/S0006-8993(01)02772-X  0.408
2001 Caligiuri MP, Peavy G, Galasko DR. Extrapyramidal signs and cognitive abilities in Alzheimer's disease. International Journal of Geriatric Psychiatry. 16: 907-11. PMID 11571772 DOI: 10.1002/Gps.443  0.507
2001 Poorkaj P, Grossman M, Steinbart E, Payami H, Sadovnick A, Nochlin D, Tabira T, Trojanowski JQ, Borson S, Galasko D, Reich S, Quinn B, Schellenberg G, Bird TD. Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. Archives of Neurology. 58: 383-7. PMID 11255441 DOI: 10.1001/Archneur.58.3.383  0.369
2001 Zhukareva V, Vogelsberg-Ragaglia V, Van Deerlin VM, Bruce J, Shuck T, Grossman M, Clark CM, Arnold SE, Masliah E, Galasko D, Trojanowski JQ, Lee VM. Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Annals of Neurology. 49: 165-75. PMID 11220736 DOI: 10.1002/1531-8249(20010201)49:2<165::Aid-Ana36>3.0.Co;2-3  0.372
2001 GOULD R, ABRAMSON I, GALASKO D, SALMON D. Rate of cognitive change in Alzheimer's disease: Methodological approaches using random effects models Journal of the International Neuropsychological Society. 7: 813-824. DOI: 10.1017/S1355617701777041  0.371
2000 Sabbagh MN, Galasko D, Koo E, Thal LJ. Amyloid-beta and treatment opportunities for Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 2: 231-59. PMID 12214087 DOI: 10.3233/Jad-2000-23-405  0.581
2000 Galasko D, Salmon D, Craig UK, Wiederholt W. The clinical spectrum of Guam ALS and Parkinson-dementia complex: 1997-1999. Annals of the New York Academy of Sciences. 920: 120-5. PMID 11193140 DOI: 10.1111/j.1749-6632.2000.tb06913.x  0.337
2000 Rockwell E, Choure J, Galasko D, Olichney J, Jeste DV. Psychopathology at initial diagnosis in dementia with Lewy bodies versus Alzheimer disease: comparison of matched groups with autopsy-confirmed diagnoses. International Journal of Geriatric Psychiatry. 15: 819-23. PMID 10984728 DOI: 10.1002/1099-1166(200009)15:9<819::AID-GPS206>3.0.CO;2-1  0.502
2000 Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, Warren K, Jeste DV. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. International Journal of Geriatric Psychiatry. 15: 794-802. PMID 10984725 DOI: 10.1002/1099-1166(200009)15:9<794::Aid-Gps178>3.0.Co;2-1  0.524
2000 Galasko DR, Gould RL, Abramson IS, Salmon DP. Measuring cognitive change in a cohort of patients with Alzheimer's disease. Statistics in Medicine. 19: 1421-32. PMID 10844707 DOI: 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1421::AID-SIM434>3.0.CO;2-P  0.474
2000 Paulsen JS, Salmon DP, Thal LJ, Romero R, Weisstein-Jenkins C, Galasko D, Hofstetter CR, Thomas R, Grant I, Jeste DV. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 54: 1965-71. PMID 10822438 DOI: 10.1212/Wnl.54.10.1965  0.636
2000 Galasko DR, Schmitt FA, Jin S, Saxton J, Bennett D, Sano M, Ferris SH. Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease Neurobiology of Aging. 21: 168. DOI: 10.1016/S0197-4580(00)82096-5  0.448
2000 Sabbagh MN, Galasko D, Koo E, Thal LJ. Amyloid-β and treatment opportunities for Alzheimer's disease Journal of Alzheimer's Disease. 2: 231-259.  0.407
1999 Teter B, Xu PT, Gilbert JR, Roses AD, Galasko D, Cole GM. Human apolipoprotein E isoform-specific differences in neuronal sprouting in organotypic hippocampal culture. Journal of Neurochemistry. 73: 2613-6. PMID 10582625 DOI: 10.1046/j.1471-4159.1999.0732613.x  0.337
1999 Clark CM, Sheppard L, Fillenbaum GG, Galasko D, Morris JC, Koss E, Mohs R, Heyman A. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Archives of Neurology. 56: 857-62. PMID 10404988 DOI: 10.1001/Archneur.56.7.857  0.444
1999 Bondi MW, Salmon DP, Galasko D, Thomas RG, Thal LJ. Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. Psychology and Aging. 14: 295-303. PMID 10403716 DOI: 10.1037//0882-7974.14.2.295  0.626
1998 Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, Thal LJ. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology. 51: 351-7. PMID 9710002 DOI: 10.1212/Wnl.51.2.351  0.737
1998 Licastro F, Davis LJ, Pedrini S, Galasko D, Masliah E. Prostaglandin E2 induced polymerization of human α-1-antichymotrypsin and suppressed its protease inhibitory activity: Implications for Alzheimer's disease Biochemical and Biophysical Research Communications. 249: 182-186. PMID 9705853 DOI: 10.1006/bbrc.1998.9103  0.414
1998 Lambert JC, Berr C, Pasquier F, Delacourte A, Frigard B, Cottel D, Pérez-Tur J, Mouroux V, Mohr M, Cécyre D, Galasko D, Lendon C, Poirier J, Hardy J, Mann D, et al. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Human Molecular Genetics. 7: 1511-6. PMID 9700208 DOI: 10.1093/Hmg/7.9.1511  0.384
1998 Connor DJ, Salmon DP, Sandy TJ, Galasko D, Hansen LA, Thal LJ. Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease. Archives of Neurology. 55: 994-1000. PMID 9678318 DOI: 10.1001/Archneur.55.7.994  0.662
1998 Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Archives of Neurology. 55: 937-45. PMID 9678311 DOI: 10.1001/Archneur.55.7.937  0.317
1998 Davies P, Resnick J, Resnick B, Gilman S, Growdon JH, Khachaturian ZS, Radebaugh TS, Roses AD, Selkoe DJ, Trojanowski JQ, Blass JP, Gibson GE, Sheu KFR, Blennow K, Delacourte A, ... ... Galasko D, et al. Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' Neurobiology of Aging. 19: 109-116. PMID 9558143 DOI: 10.1016/S0197-4580(98)00022-0  0.473
1998 JIN S, THOMAS R, GALASKO D, THAL L. Dynamic measurement scale development for clinical trials in targeted populations Controlled Clinical Trials. 19: S58-S58. DOI: 10.1016/S0197-2456(98)80153-0  0.476
1997 Lambert JC, Pérez-Tur J, Dupire MJ, Galasko D, Mann D, Amouyel P, Hardy J, Delacourte A, Chartier-Harlin MC. Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Human Molecular Genetics. 6: 2151-4. PMID 9328480 DOI: 10.1093/Hmg/6.12.2151  0.406
1997 Crook R, Ellis R, Shanks M, Thal LJ, Perez-Tur J, Baker M, Hutton M, Haltia T, Hardy J, Galasko D. Early-onset Alzheimer's disease with a presenilin-1 mutation at the site corresponding to the Volga German presenilin-2 mutation. Annals of Neurology. 42: 124-8. PMID 9225696 DOI: 10.1002/Ana.410420121  0.525
1997 Olichney JM, Sabbagh MN, Hofstetter CR, Galasko D, Grundman M, Katzman R, Thal LJ. The impact of apolipoprotein E4 on cause of death in Alzheimer's disease. Neurology. 49: 76-81. PMID 9222173 DOI: 10.1212/Wnl.49.1.76  0.694
1997 Davis RE, Miller S, Herrnstadt C, Ghosh SS, Fahy E, Shinobu LA, Galasko D, Thal LJ, Beal MF, Howell N, Parker WD. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 94: 4526-31. PMID 9114023 DOI: 10.1073/Pnas.94.9.4526  0.524
1997 Galasko D, Clark C, Chang L, Miller B, Green RC, Motter R, Seubert P. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 48: 632-5. PMID 9065538 DOI: 10.1212/Wnl.48.3.632  0.498
1997 Johnson GV, Seubert P, Cox TM, Motter R, Brown JP, Galasko D. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. Journal of Neurochemistry. 68: 430-3. PMID 8978756 DOI: 10.1046/j.1471-4159.1997.68010430.x  0.439
1997 Mackell JA, Ferris SH, Mohs R, Schneider L, Galasko D, Whitehouse P, Schmitt F, Sano M, Thal LJ. Multicenter Evaluation of New Instruments for Alzheimerʼs Disease Clinical Trials Alzheimer Disease & Associated Disorders. 11: 65-69. DOI: 10.1097/00002093-199700112-00010  0.498
1997 Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S. An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease Alzheimer Disease & Associated Disorders. 11: 33-39. DOI: 10.1097/00002093-199700112-00005  0.438
1997 Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, Schmitt FA, Sano M, Thomas RG, Ernesto C, Grundman M, Schafer K, Thal LJ. A Multicenter Evaluation of New Treatment Efficacy Instruments for Alzheimerʼs Disease Clinical Trials Alzheimer Disease & Associated Disorders. 11: 1-12. DOI: 10.1097/00002093-199700112-00002  0.489
1996 Peavy GM, Salmon DP, Rice VA, Galasko D, Samuel W, Taylor KI, Ernesto C, Butters N, Thal L. Neuropsychological assessment of severely demeted elderly: the severe cognitive impairment profile. Archives of Neurology. 53: 367-72. PMID 8929160 DOI: 10.1001/Archneur.1996.00550040107020  0.61
1996 McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 47: 1113-24. PMID 8909416 DOI: 10.1212/Wnl.47.5.1113  0.495
1996 Galasko D, Katzman R, Salmon DP, Hansen L. Clinical and neuropathological findings in Lewy body dementias. Brain and Cognition. 31: 166-75. PMID 8811993 DOI: 10.1006/brcg.1996.0040  0.678
1996 Salmon DP, Galasko D, Hansen LA, Masliah E, Butters N, Thal LJ, Katzman R. Neuropsychological deficits associated with diffuse Lewy body disease. Brain and Cognition. 31: 148-65. PMID 8811990 DOI: 10.1006/Brcg.1996.0039  0.722
1996 Chen X, Xia Y, Gresham LS, Molgaard CA, Thomas RG, Galasko D, Wiederholt WC, Saitoh T. ApoE and CYP2D6 polymorphism with and without parkinsonism-dementia complex in the people of Chamorro, guam. Neurology. 47: 779-84. PMID 8797479 DOI: 10.1212/Wnl.47.3.779  0.431
1996 Ellis RJ, Caligiuri M, Galasko D, Thal LJ. Extrapyramidal motor signs in clinically diagnosed Alzheimer disease. Alzheimer Disease and Associated Disorders. 10: 103-14. PMID 8727172 DOI: 10.1097/00002093-199601020-00008  0.654
1996 Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R, Thal LJ. The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology. 47: 190-6. PMID 8710076 DOI: 10.1212/Wnl.47.1.190  0.717
1996 Katzman R, Galasko DR, Saitoh T, Chen X, Pay MM, Booth A, Thomas RG. Apolipoprotein-epsilon4 and head trauma: Synergistic or additive risks? Neurology. 46: 889-91. PMID 8618734  0.444
1996 Koss E, Edland S, Fillenbaum G, Mohs R, Clark C, Galasko D, Morris JC. Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer's disease: A CERAD analysis, part XII Neurology. 46: 136-141. PMID 8559362 DOI: 10.1212/Wnl.46.1.136  0.456
1996 Schafer K, Thomas R, Galasko D, Morris JC, Whitehouse P, Bochenek J, Thal L. P63 Informed consent issues when including genetic testing in clinical trials Controlled Clinical Trials. 17: S130-S131. DOI: 10.1016/0197-2456(96)84683-6  0.476
1995 Bondi MW, Salmon DP, Monsch AU, Galasko D, Butters N, Klauber MR, Thal LJ, Saitoh T. Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Neurology. 45: 2203-6. PMID 8848194 DOI: 10.1212/Wnl.45.12.2203  0.561
1995 Katzman R, Galasko D, Saitoh T, Thal LJ, Hansen L. Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Brain and Cognition. 28: 259-65. PMID 8546853 DOI: 10.1006/Brcg.1995.1256  0.722
1995 Corey-Bloom J, Thal LJ, Galasko D, Folstein M, Drachman D, Raskind M, Lanska DJ. Diagnosis and evaluation of dementia. Neurology. 45: 211-8. PMID 7854514 DOI: 10.1212/Wnl.45.2.211  0.686
1995 Saitoh T, Xia Y, Chen X, Masliah E, Galasko D, Shults C, Thal LJ, Hansen LA, Katzman R. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Annals of Neurology. 37: 110-2. PMID 7818242 DOI: 10.1002/Ana.410370120  0.708
1995 Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E. The consortium to establish a registry for alzheimer's disease (cerad).: Part xi. clinical milestones in patients with alzheimer's disease followed over 3 years Neurology. 45: 1451-1455. PMID 7644039 DOI: 10.1212/WNL.45.8.1451  0.525
1995 Olichney JM, Hofstetter CR, Galasko D, Thal LJ, Katzman R. Death certificate reporting of dementia and mortality in an Alzheimer's disease research center cohort. Journal of the American Geriatrics Society. 43: 890-3. PMID 7636097 DOI: 10.1111/J.1532-5415.1995.Tb05532.X  0.683
1995 Corey-Bloom J, Galasko D. Adjunctive therapy in patients with Alzheimer's disease. A practical approach. Drugs & Aging. 7: 79-87. PMID 7579786 DOI: 10.2165/00002512-199507020-00002  0.549
1995 Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Annals of Neurology. 38: 643-8. PMID 7574461 DOI: 10.1002/Ana.410380413  0.371
1994 Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, Hill LR, Lessin P, Thal LJ. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Archives of Neurology. 51: 888-95. PMID 8080388 DOI: 10.1001/archneur.1994.00540210060013  0.72
1994 Galasko D, Saitoh T, Xia Y, Thal LJ, Katzman R, Hill LR, Hansen L. The apolipoprotein E allele epsilon 4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease. Neurology. 44: 1950-1. PMID 7936253 DOI: 10.1212/Wnl.44.10.1950  0.718
1994 Hansen LA, Galasko D, Samuel W, Xia Y, Chen X, Saitoh T. Apolipoprotein-E epsilon-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease. Neuroscience Letters. 182: 63-5. PMID 7891889 DOI: 10.1016/0304-3940(94)90206-2  0.498
1994 Bondi MW, Monsch AU, Galasko D, Butters N. Preclinical cognitive markers of dementia of the Alzheimer type. Neuropsychology (Journal). 8: 374-384. DOI: 10.1037//0894-4105.8.3.374  0.456
1993 Corey-Bloom J, Galasko D, Hofstetter CR, Jackson JE, Thal LJ. Clinical features distinguishing large cohorts with possible AD, probable AD, and mixed dementia. Journal of the American Geriatrics Society. 41: 31-7. PMID 8418119 DOI: 10.1111/J.1532-5415.1993.Tb05944.X  0.737
1993 Galasko D, Abramson I, Corey-Bloom J, Thal LJ. Repeated exposure to the Mini-Mental State Examination and the Information-Memory-Concentration Test results in a practice effect in Alzheimer's disease. Neurology. 43: 1559-63. PMID 8351011 DOI: 10.1212/Wnl.43.8.1559  0.678
1993 Morris JC, Edland S, Clark C, Galasko D, Koss E, Mohs R, Van Belle G, Fillenbaum G, Heyman A. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease Neurology. 43: 2457-2465. PMID 8255439 DOI: 10.1212/Wnl.43.12.2457  0.495
1993 Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa. Journal of Neuropathology and Experimental Neurology. 52: 648-54. PMID 8229084 DOI: 10.1097/00005072-199311000-00012  0.474
1993 Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, Bryant K, Fritz LC, Galasko D, Thal LJ. Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature. 361: 260-3. PMID 7678698 DOI: 10.1038/361260a0  0.501
1991 Galasko D, Corey-Bloom J, Thal LJ. Monitoring progression in Alzheimer's disease. Journal of the American Geriatrics Society. 39: 932-41. PMID 1842209 DOI: 10.1111/J.1532-5415.1991.Tb04463.X  0.741
1990 Galasko D, Kwo-on-Yuen PF, Klauber MR, Thal LJ. Neurological findings in Alzheimer's disease and normal aging. Archives of Neurology. 47: 625-7. PMID 2346387 DOI: 10.1001/Archneur.1990.00530060033012  0.649
1990 Galasko D, Klauber MR, Hofstetter CR, Salmon DP, Lasker B, Thal LJ. The Mini-Mental State Examination in the early diagnosis of Alzheimer's disease. Archives of Neurology. 47: 49-52. PMID 2294894 DOI: 10.1001/archneur.1990.00530010061020  0.589
1990 Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology. 40: 1-8. PMID 2153271 DOI: 10.1212/Wnl.40.1.1  0.657
1990 Katzman R, Alford M, Butters N, DeTeresa R, Galasko DR, Hofstetter CR, Klauber M, Hansen LA, Masliah E, Pay MM, Rice V, Salmon D, Thai L. Reply from the Authors Neurology. 40: 1149-1149. DOI: 10.1212/WNL.40.7.1149-a  0.379
1990 Hansen L, Galasko D, Katzman R, Thal L, Alford M, Salmon D, Masliah E, DeTeresa R, Butters N. Reply from the Authors Neurology. 40: 1148-1148. DOI: 10.1212/WNL.40.7.1148  0.379
Show low-probability matches.